Cab Molecules

ABSTRACT

The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy.

FIELD OF THE INVENTION

The present invention relates to CAB molecules, ADEPT constructs directed against CEA and their use in therapy.

BACKGROUND

Traditional therapeutic molecules circulate freely throughout the body of patients until they are removed from circulation by the liver or another mechanism of clearance. Such non-targeted molecules can exert pharmacological effects indiscriminately on a wide range of cells and tissues. Indiscriminate targeting can cause serious side effects in a patient. The problem may be particularly acute when the molecule is highly toxic (e.g., in the case of a chemotherapeutic agent where the therapeutic window, the difference between an efficacious and injurious or even lethal dose, can be small).

In recent years, researchers have attempted to develop compounds that specifically affect particular groups of cells, tissues or organs. Most of the compounds target a particular tissue by preferentially binding a particular target molecule displayed by the tissue. By preferentially affecting targeted cells, tissues or organs, the therapeutic window can be increased, which in turn increases the opportunity for a successful treatment regimen and/or reduces the occurrence of side effects.

Preferential binding is employed in antibody-directed enzyme prodrug therapy (ADEPT). See, e.g., Xu et al., 2001, Clin Cancer Res. 7:3314-24.; Denny, 2001, Eur J Med Chem. 36:577-95. In ADEPT, an antibody or antibody fragment is linked to an enzyme capable of converting an inactive pro-drug into an active cytotoxic agent. An ADEPT conjugate is administered to a patient, and the conjugate is localized to a target tissue via antibody/antigen binding. The prodrug is subsequently administered, and the prodrug circulates throughout the patient's body but causes few or no side effects because the prodrug is in the inactive form and is activated by the ADEPT antibody-enzyme conjugate only in the vicinity of the target tissue. Thus, a relatively low concentration of active drug is present throughout the body, but a relatively high concentration of active drug is produced in the vicinity of the target tissue, increasing the therapeutic window of the toxin at the desired site.

In ADEPT, the antibody or antibody portion of a construct binds to an antigen to achieve localization, so selecting the proper antigen is important (e.g., an antigen that has a high tumor/normal expression profile). An antigen of particular interest frequently found on the cell surface in cancer tissues is carcinoembryonic antigen (CEA). CEA was first described by Gold and Freedman, J. Exp. Med., 121, 439-462, (1965). CEA is highly expressed in tumor tissue and also found at a lower concentration in some normal organs, particularly in the digestive tract.

Many antibodies to tumor antigens cross-react with related antigens. Systemic application of a MAb that is cross-reactive with a related antigen must be avoided to preclude risk of potentially severe side effects. Accordingly, the development of antigen-specific monoclonal antibodies for in vitro and in vivo diagnosis and therapy requires a good knowledge of the number, quality and biodistribution of related cross-reactive antigens. Careful immunochemical characterization of the MAb to be used is required with respect to its specificity and affinity for the target antigen and for related antigens.

Murine MAb T84.66 (ATCC Accession No. BH 8747) IgG1, k shows a high affinity constant to CEA and no cross reactivity to other members of the CEA gene family. A significant potential side effect of ADEPT therapy is the development of antibodies against the targeted enzyme during therapy. The production of human anti-mouse antibodies (HAMA) leads to reduced efficiency of the MAb and to potentially serious manifestations of acute and chronic allergic complications for the patient. See Levy, et al. Ann. Rev. Med. 34:107-116 (1983); Houghton, et al. Proc. Natl. Acad. Sci. USA, 82:1242-1246 (1985) and Sears, et al. J. Biol. Resp. Modifiers 3:138-150 (1984). Antibody formation has been observed during a clinical trial of a CEA-directed antibody-enzyme conjugate two weeks after treatment, which prevented subsequent rounds of treatment [Napier, M. P., S. K. Sharma, C. J. Springer, K. D. Bagshawe, A. J. Green, J. Martin, S. M. Stribbling, N. Cushen, D. O'Malley and R. H. Begent (2000) Clin Cancer Res 6, 765-72, Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma].

The risk of eliciting an immune reaction is high for microbial proteins. The use of human enzymes for ADEPT has been investigated in pre-clinical studies [Smith, G. K., S. Banks, T. A. Blumenkopf, M. Cory, J. Humphreys, R. M. Laethem, J. Miller, C. P. Moxham, R. Mullin, P. H. Ray, L. M. Walton and L. A. Wolfe, 3rd (1997) J Biol Chem 272, 15804-16, Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate]. Although the risk of antibody formation can be reduced for human protein as compared to microbial protein, human proteins can also elicit immune reactions when administered to people. The consequences of eliciting an immune reaction against a human protein can be very significant, as such a treatment could trigger an auto-immune disease.

The risk of eciciting an immune reaction may be great for an ADEPT construct that contains at least two potential risks: the antibody portion and the enzyme portion.

SUMMARY OF THE INVENTION

The present invention relates to CAB molecules, ADEPT constructs directed against CEA and their use in therapy, especially with prodrugs as described herein. The molecules of the current invention have been preferably deimmunized and do not elicit an immune response and can be produced in high yield.

In a first aspect, the CAB molecule comprises an antibody/enzyme conjugate, wherein the antibody portion binds to CEA. In a preferred embodiment, the enzyme comprises a beta-lactamase.

In a preferred embodiment, the CAB molecule has an unmodified amino acid sequence. In a preferred embodiment, the CAB molecule has an amino acid sequence modified from the amino acid sequence set forth in SEQ ID NO:2, and the modification is located at least one of positions 12, 72, 283 or 586, wherein position numbering is with respect to SEQ ID NO:2 as shown in FIG. 4. In a preferred embodiment, the CAB molecule has both of the following modifications: 12 and 72. In a preferred embodiment, the CAB molecule has all of the following modifications: 12, 72, 283 and 586.

In a preferred embodiment, the CAB molecule has at least one of the following modifications: A12S, R72G, K283A or S586A, wherein position numbering is with respect to SEQ ID NO:2 as shown in FIG. 4. In a preferred embodiment, the CAB molecule comprises a CAB1.11 molecule, the CAB1.11 molecule comprising the following modifications: A12S and R72G. In a preferred embodiment, the CAB molecule comprises a CAB1.11i molecule, the CAB1.11i molecule comprising the following modifications: A12S, R72G, K283A and S586A.

In a preferred embodiment, the CAB molecule comprises CAB 1.10 having SEQ ID NO:2, CAB1.11 having SEQ ID NO:7 or CAB1.11i having SEQ ID NO:8.

In a second aspect, the invention is drawn to a nucleic acid encoding a CAB molecule as set forth herein. In a third aspect, the invention is drawn to treating a subject in need thereof, comprising administering to the subject a CAB molecule, as provided herein, and a prodrug that is a substrate of the CAB molecule. In a fourth aspect, the invention is drawn to a pharmaceutical composition comprising a CAB molecule.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 sets forth unmodified sequences disclosed in the invention. FIG. 1A (SEQ ID NO:1) sets forth the amino acid sequence of the T84.66 antibody as described in Shively et al. and as disclosed in the invention provided herein; FIG. 1B sets forth the nucleotide sequence of the T84.66-derived antibody (SEQ ID NO:3); FIG. 1C sets forth the amino acid sequence for BLA (SEQ ID NO: 11); FIG. 1D sets forth the nucleotide sequence for BLA (SEQ ID NO:12); FIG. 1E sets forth the amino acid sequence for the 1.10 (SEQ ID NO: 2) construct that is T84.66 fused to BLA and includes a linker; FIG. 1F sets forth the nucleotide sequence for the 1.10 construct (SEQ ID NO:4). Underlining indicates the scFv portion of the molecule, and italics indicate the linker between the vl and vh portions of the scFv.

FIG. 2 sets forth the modified CAB 1.11 antibody portion of the current invention. FIG. 2A sets forth the amino acid sequence that has been modified and comprises a CAB 1.11 antibody portion (SEQ ID NO:5); FIG. 2B sets forth the nucleotide sequence sequence (SEQ ID NO:6) that has been modified and comprises a CAB1.11 antibody portion.

FIG. 3 sets forth amino acid sequence of the deimmunized BLA portion (SEQ ID NO:13). Mutations from unmodified BLA (provided in FIG. 1) are shown in bold; numbering has been retained to remain consistent with the CAB1.11i construct.

FIG. 4 sets forth sequences for the CAB1.11 and CAB1.11i molecules. FIG. 4A sets forth the amino acid sequence of the CAB1.11 molecule (SEQ ID NO:7), which includes an antibody portion modified to improve expression, as described in the Examples, and also includes the BLA portion; FIG. 4B sets forth the nucletotide sequence of the CAB1.11 molecule (SEQ ID NO:9); FIG. 4C sets forth the amino acid sequence of the CAB1.11i molecule (SEQ ID NO:8), which includes the deimmunized BLA portion, as set forth in the Examples; FIG. 4D sets forth the nucletotide sequence that encodes the CAB1.11i molecule (SEQ ID NO:10), FIG. 4E sets forth the nucleotide sequence that encodes the plasmid, pHR19.2. In the Figure showing the CAB1.11i molecule, the scFv portion of the molecule has been underlined. The four mutations described in the Examples herein have been underlined. The linkers provided herein have been italicized. Two of the mutations are in the scFv portion of the molecule, and two of the mutations are in the BLA portion of the molecule.

FIG. 5 shows the plasmid map for pHR19.2.

FIG. 6 sets forth the binding of variants to target CEA. The x-axis shows the variant designation, as described herein, and the y-axis shows the % specific binding.

FIG. 7 shows a graph setting forth the results from the fermentation runs of EB101.1/pHR19.2 as set forth in Example 6. The x-axis shows EFT measured in hours, and the y-axis shows lactamase activity, measured in mg/L.

FIG. 8 sets forth the purification process for CAB1.11i, as described in Example 7.

FIG. 9 shows an SDS PAGE electrophoresis of CAB 1.11i. Lane 1 shows a molecular weight standard, lanes 3-5 show unrelated proteins and lane 6 shows 1.11i.

FIG. 10 shows binding and off-rate curves for CAB1.11i. FIG. 10A shows a binding curve, the x-axis showing amount, in nM, of CAB1.11i bound, and the y-axis shows how much CAB1.11i was added, again shown in nM. FIG. 10B shows off-rate, as described in Example 9, with time measured in minutes on the y-axis and percent BLA activity bound shown on the x-axis.

FIG. 11 shows CD, as set forth in Example 10.

FIG. 12 is a graph demonstrating tissue localization of CAB 1.11i. The x-axis shows time after administration, in hours, of the CAB 1.11i construct. The y-axis shows concentration in ug/g, of the CAB construct in different organs, as indicated by color, as shown in the chart at the right. The graph shows that CAB1.11i was eliminated rapidly from plasma, liver and kidney and localized to tumor.

FIG. 13 shows the tumor to blood ratio of CAB 1.11i. The x-axis shows time, in hours, after administration of the CAB 1.11i construct. The y-axis shows the level of tumor to blood. High tumor to blood ratios were achieved and sustained.

FIG. 14 shows demonstrated activity in a human colorectal cancer xenograft mouse model. The x-axis shows day number. The y-axis shows tumor volume measured in cubic millimeters. See, for example, Example 12.

FIG. 15 shows the results of IHC staining as set forth in Example 14. Column I shows Case ID; column 4 shows sample pathology; column 5 shows sample diagnosis; column 6 shows tissue of origin/site of finding; column 7 shows results of H&E staining, as set forth in Examples; column 8 shows results of staining against the control, human cytokeratin; columns 9-12 show results of staining against relevant CAB; column 13 shows results of no antibody staining.

FIG. 16 shows relevant plasma/tumor concentrations. FIG. 16A shows plasma and tumor CAB 1.11i concentration-time profiles (log-linear scale). The x-axis shows time, in hours, and the y-axis shows concentration. FIG. 16B shows dosing interval related to plasma GC-mel and melphalan exposure. Top right and left show GC-Mel and Mel, respectively, with the x-axis showing time, in hours, and the y-axis showing concentration. The bottom graphs, right and left, show GC-Mel and Mel, respectively, with the y-axis being the AUC and the bars, as indicated, being time, in hours.

FIG. 17 shows that plasma and kidney exposure to Mel is decreased with increased interval between CAB 1.11i and GC-Mel doses. The x-axis shows AUC, and the y-axis shows time, in hours. Codes for kidney, plasma and tumor are indicated in the inset legend, at right.

FIG. 18 shows that efficacious tumor melphalan exposures are achieved at each time period while systemic melphalan exposure is decreased. The y-axis shows AUC, and the x-axis indicates the sample, plasma or tumor. Time is as set forth in the inset at the right of graph.

FIG. 19 shows the average tumor volume (19A) and average body weight (19B), as set forth in Example 16. The x-axis shows time, measured in days, and the y-axis shows tumor volume, measured in mm³, and percent body weight change, respectively.

FIG. 20 shows the results of a possible or potential immunogen, specifically CAB1.11i or wt BLA administered IV or CAB1.11i, wt BLA or BLAi administered IP. The x-axis shows the molecule or test article or protein administered, and the y-axis shows response, as measured in IgG antibodies.

FIG. 21 shows the results of the dose-ranging efficacy study, as set forth in Example 18. The Figure shows efficacy of several dose levels of GC-mel, with the x-axis showing days post-CAB 1.11i dose, and the y-axis showing tumor volume, as measured in mm³.

FIG. 22 shows the results of the dose ranging profile of GC-Mel administered after CAB1.11i in NCR nude mice bearing TLS174T xemograft tumors, specifically the average percent body weight loss, as set forth in Example 19. FIGS. 22A and 22B shows the average percent body weight loss with a dosing interval of 72 hours and 96 hours, respectively. The x-axis shows time in days, and the y-axis shows the average percent body weight change. The inset provides a key as to administered drug.

FIG. 23 shows CAB1.11i plasma concentration-time profile in rats as set forth in Example 20. The left graph shows female rats, and the right graph shows male rats. The x-axis shows time in hours, and the y-axis shows concentration of CAB1.11i.

FIG. 24 shows the pharmacokinetics of CAB1.11i following intravenous bolus administration to Sprague-Dawley rats. Specifically, FIG. 24A shows CAB1.11 i concentration-time profiles in rats, as set forth in Example 21. The x-axis shows time in hours, and the y-axis shows concentration. FIG. 24B shows the plasma concentration-time profiles in rats, the x-axis showing time, in hours, and the y-axis shows concentration. The inset shows symbols for two representative CAB1.11i (circles and squares, 15% dimer and monomer, respectively)

FIG. 25 shows CAB1.11i concentration-time profiles in cynomolgus monkey following 2 weekly doses. The x-axis shows time, in hours, and the y-axis shows concentration of CAB1.11i. The inset provides a legend, with F and M standing for female and male, respectively.

FIG. 26 shows CAB1.11i with or without CEA coadministration, as set forth in Example 22. The x-axis shows time, in hours, and the y-axis shows CAB1.11i concentration.

DETAILED DESCRIPTION OF THE INVENTION

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described. For purposes of the present invention, the following terms are used as described below.

“CAB” molecule shall mean a targeted agent that binds to a carcinoembryonic antigen (CEA) target or microtarget and an enzyme, such as BLA. A CAB molecule may have an unmodified sequence or a modified sequence, wherein the unmodified sequence comprises the amino acid sequence set forth in SEQ ID NO:2 SEQ ID NO:2 sets forth a CAB molecule that includes BLA as shown in FIG. 4. Position numbering as described in this document is with respect to SEQ ID NO:2, as set forth FIG. 4.

A “modified” sequence refers to a sequence that includes at least one mutation.

An “unmodified” sequence, as set forth herein, refers to a sequence that has not been modified and, thus, does not include at least one mutation, as set forth herein. Examples of unmodified sequences of the invention include, but may not be limited to, T84.66 (SEQ ID NO:1), CAB 1.10 (SEQ ID NO:2) and BLA (SEQ ID NO:11). Unmodified sequences may be modified, as described herein, to produce preferred embodiments of the invention.

A “targeted agent” is a chemical entity that binds selectively to a microtarget of interest. Examples of targeted agents are antibodies, peptides and inhibitors. Of interest are targeted enzymes that have a desired catalytic activity and that can bind to one or more target structures with high affinity and selectivity. Targeted enzymes retain at least most of their activity while bound to a target.

A “binding moiety” is a part of a targeted agent (or an ADEPT construct, e.g., CAB molecule) that binds a microtarget. A binding moiety can comprise more than one region, either contiguous or non-contiguous, of a CAB.

An “active moiety” is a part of a targeted agent (or an ADEPT construct, e.g., CAB molecule) that confers functionality to the agent. An active moiety can comprise more than one region, either contiguous or non-contiguous, of, for example, a CAB molecule. In particular, an active moiety can be a beta-lactamase.

The term “protein” is used interchangeably here with the terms “peptide” and “polypeptide,” and refers to a molecule comprising two or more amino acid residues joined by a peptide bond.

The terms “cell”, “cell line”, and “cell culture” can be used interchangeably and all such designations include progeny. The words “transformants” or “transformed cells” include the primary transformed cell and cultures derived from that cell without regard to the number of transfers. All progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same functionality as screened for in the originally transformed cell are included in the definition of transformants. The cells can be prokaryotic or eukaryotic.

The term “oligonucleotide” as used herein is defined as a molecule comprised of two or more deoxyribonucleotides or ribonucleotides. The exact size will depend on many factors, which in turn depend on the ultimate function or use of the oligonucleotide. Oligonucleotides can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a method such as the phosphotriester method of Narang et al., 1979, Meth. Enzymol. 68:90-99; the phosphodiester method of Brown et al., 1979, Meth. Enzymol. 68:109-151; the diethylphosphoramidite method of Beaucage et al., 1981, Tetrahedron Lett. 22:1859-1862; and the solid support method of U.S. Pat. No. 4,458,066, each incorporated herein by reference. A review of synthesis methods is provided in Goodchild, 1990, Bioconjugate Chemistry 1(3):165-187, incorporated herein by reference.

The term “primer” as used herein refers to an oligonucleotide capable of acting as a point of initiation of synthesis when placed under conditions in which primer extension is initiated. Synthesis of a primer extension product that is complementary to a nucleic acid strand is initiated in the presence of the requisite four different nucleoside triphosphates and a DNA polymerase in an appropriate buffer at a suitable temperature. A “buffer” includes a buffer, cofactors (such as divalent metal ions) and salt (to provide the appropriate ionic strength), adjusted to the desired pH.

A primer that hybridizes to the non-coding strand of a gene sequence (equivalently, is a subsequence of the noncoding strand) is referred to herein as an “upstream” or “forward” primer. A primer that hybridizes to the coding strand of a gene sequence is referred to herein as a “downstream” or “reverse” primer.

Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., asparagine, glutamine, serine, threonine, tyrosine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, cysteine, glycine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Standard three-letter or one-letter amino acid abbreviations are used herein. Equivalent substitutions may be included within the scope of the claims.

The peptides, polypeptides and proteins of the invention can comprise one or more non-classical amino acids. Non-classical amino acids include but are not limited to the D-isomers of the common amino acids, α-amino isobutyric acid, 4-aminobutyric acid (4-Abu), 2-aminobutyric acid (2 Abu), 6-amino hexanoic acid (Ahx), 2-amino isobutyric acid (2-Aib), 3-amino propionoic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β-alanine, fluoro-amino acids, designer amino acids such as β-methyl amino acids, Cα-methyl amino acids, Nα-methyl amino acids, and amino acid analogs in general.

The term “Ab” or “antibody” refers to polyclonal and monoclonal antibodies (MAb), chimeric antibodies, humanized antibodies, human antibodies, immunoglobulins or antibody or functional fragments of an antibody that binds to a target antigen. Examples of such functional entities include complete antibody molecules, antibody fragments, such as Fv, single chain Fv, complementarity determining regions (CDRs), V_(L) (light chain variable region), V_(H) (heavy chain variable region) and any combination of those or any other functional portion of an immunoglobulin peptide capable of binding to target antigen. In Example 1, the construct has the following order: vL-(GGGGS)₆-vH; however, the example is non-limiting, and all orders of vL and vH, are contemplated to be within the scope of the invention. Furthermore, the length of the linker need not be 30 amino acids in length, as disclosed herein, and different linker lengths are contemplated to be within the scope of the invention.

The term “prodrug” refers to a compound that is converted via one or more enzymatically-catalyzed or physiologically-catalyzed steps into an active compound that has an increased pharmacological activity relative to the prodrug. A prodrug can comprise a pro-part or inactive moiety and a drug or active drug or detectable moiety. Optionally, the prodrug also contains a linker. For example, the prodrug can be cleaved by an enzyme to release an active drug. Alternatively, an enzyme could alter the prodrug to release a detectable moiety. In a more specific example, prodrug cleavage by the targeted enzyme releases the active drug into the vicinity of the target bound to the targeted enzyme. “Pro-part” and “inactive moiety” refer to the inactive portion of the prodrug after it has been converted. For example, if a prodrug comprises a PEG molecule linked by a peptide to an active drug, the pro-part is the PEG moiety with or without a portion of the peptide linker.

As used herein, “GC-Mel” shall refer to the prodrug glutaryl-cephalosporin-melphalan as disclosed, for example, in Senter et al., U.S. Pat. No. 5,773,435, which is incorporated by reference herein, including any drawingsThe term “drug” and “active drug” and “detectable moiety” refer to the active moieties of a prodrug. After cleavage of the prodrug by a targeted enzyme, the active drug acts therapeutically upon the targeted tumor, cell, infectious agent or other agent of disease. The detectable moiety acts as a diagnostic tool, and such detectable moieties are intended to be within the scope of the claims. The active drug can be any chemical entity that is able to kill a cell, inhibit cell proliferation or act in concert with another drug to facilitate cell killing or inhibition of cell proliferation (e.g., drugs that predispose cells to apopotosis).

As used herein, “Mel” shall mean Melphalan. The structure of Mel is well known in the art and can also be found in U.S. Pat. No. 5,773,435.

As used herein, “dosing interval” shall mean the interval between administration of the protein and subsequent administration of the pro-drug. For example, in Example 20, dosing intervals of 72 and 96 hours are given, as set forth in Example 18.

As used herein, “cycle” shall mean the interval between one round or therapy of protein and prodrug and the next round, whatever that round may be

The term “% sequence homology” is used interchangeably herein with the terms “% homology,” “% sequence identity” and “% identity” and refers to the level of amino acid sequence identity between two or more peptide sequences, when aligned using a sequence alignment program. For example, as used herein, 80% homology means the same thing as 80% sequence identity determined by a defined algorithm, and accordingly, a homologue of a given sequence has greater than 80% sequence identity over a length of the given sequence. Exemplary levels of sequence identity include, but are not limited to, 60, 70, 80, 85, 90, 95, 98 or 99% or more sequence identity to a given sequence.

Exemplary computer programs that can be used to determine identity between two sequences include, but are not limited to, the suite of BLAST programs, e.g., BLASTN, BLASTX, and TBLASTX, BLASTP and TBLASTN, which are well-known to one skilled and the art. See also Altschul et al., 1990, J. Mol. Biol. 215: 403-10 and Altschul et al., 1997, Nucleic Acids Res., 25:3389-3402. Sequence searches are typically carried out using the BLASTP program when evaluating a given amino acid sequence relative to amino acid sequences in the GenBank Protein Sequences and other public databases. The BLASTX program is preferred for searching nucleic acid sequences that have been translated in all reading frames against amino acid sequences in the GenBank Protein Sequences and other public databases. Both BLASTP and BLASTX are run using default parameters of an open gap penalty of 11.0, and an extended gap penalty of 1.0, and utilize the BLOSUM-62 matrix. See Altschul, et al., 1997.

A preferred alignment of selected sequences in order to determine “% identity” between two or more sequences, is performed using for example, the CLUSTAL-W program in MacVector version 6.5, operated with default parameters, including an open gap penalty of 10.0, an extended gap penalty of 0.1, and a BLOSUM 30 similarity matrix.

The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy, especially with prodrugs as described herein. The molecules of the current invention have been preferably deimmunized and do not elicit an immune response.

In a first aspect, the CAB molecule comprises an antibody/enzyme conjugate, wherein the antibody portion binds to CEA. In a preferred embodiment, the enzyme comprises a beta-lactamase.

In a preferred embodiment, the CAB molecule has an unmodified amino acid sequence. In a preferred embodiment, the CAB molecule has an amino acid sequence modified from the amino acid sequence set forth in SEQ ID NO:2, and the modification is located at least one of positions 12, 72, 283 or 586, wherein position numbering is with respect to SEQ ID NO:2 as shown in FIG. 4. In a preferred embodiment, the CAB molecule has both of the following modifications: 12 and 72. In a preferred embodiment, the CAB molecule has all of the following modifications: 12, 72, 283 and 586.

In a preferred embodiment, the CAB molecule has at least one of the following modifications: A12S, R72G, K283A or S586A, wherein position numbering is with respect to SEQ ID NO:2 as shown in FIG. 4. In a preferred embodiment, the CAB molecule comprises a CAB1.11 molecule, the CAB1.11 molecule comprising the following modifications: A12S and R72G. In a preferred embodiment, the CAB molecule comprises a CAB1.11i molecule, the CAB1.11i molecule comprising the following modifications: A12S, R72G, K283A and S586A.

In a preferred embodiment, the CAB molecule comprises CAB 1.10 having SEQ ID NO:2, CAB1.11 having SEQ ID NO:7 or CAB1.11i having SEQ ID NO:8.

In another embodiment, the CAB is an MDTA as described in PCT Application Number US03/18200, filed Jun. 12, 2002 and incorporated herein by reference in its entirety. Some of the CAB molecules of the present invention have been shown to preferentially bind to a microtarget present on a target relative to binding of a non-target. The difference in binding can be caused by any difference between the target and non-target such as, for example, a difference in pH, oxygen pressure, concentration of solutes or analytes (e.g., lactic acid, sugars or other organic or inorganic molecules), temperature, light or ionic strength. Preferential binding of the CABs of the current invention can be used to bind to a microtarget under a desired set of conditions, identify a target in vitro, ex vivo, in situ or in vivo (e.g., a target tissue in a subject), kill a target cell or tissue, convert a prodrug into an active drug in or near a target tissue. It also can be used as a surface catalyst, for example, a targeted laccase. Other uses include, e.g., targeted generation of a compound (e.g., H₂O₂ from glucose) and the targeted destruction of compounds (e.g., a metabolite or signalling molecule from a particular tissue).

In one embodiment, the CAB is selected, made or modified using an affinity maturation method, e.g., as described in PCT application US03/18187, with a priority date filed Jun. 12, 2002 and incorporated herein by reference in its entirety.

In another embodiment, the CAB is selected, made or modified using a loop-grafting method, e.g., as described in U.S. patent application Ser. No. 10/170,387, filed Jun. 12, 2002 and incorporated herein by reference in its entirety.

In another embodiment, the CAB is a multifunctional polypeptide, e.g., as described in U.S. patent application Ser. No. 10/170,729, filed Jun. 12, 2002 and incorporated herein by reference in its entirety.

In another embodiment, the CABs of the invention are used for diagnostic or therapeutic applications such as those disclosed, for example, in U.S. Pat. No. 4,975,278, which is incorporated herein by reference in its entirety, as well as methods well-known in the art.

In one embodiment, the CAB molecule further comprises an active moiety. The active moiety can be any molecule, or a part of a molecule, that has an activity. The activity can be any activity. Examples of types of activities that the active moiety can have include, for example, a detectable activity, an enzymatic activity, a therapeutic activity, a diagnostic activity, a toxic activity or a binding activity. The active moiety can be a discrete part of the CAB, for example, an enzyme that is fused or conjugated to the binding moiety, or it can be an integral part of the CAB, for example, binding of the CAB to the microtarget can activate or inhibit an activity of the microtarget or the target, or the CAB can be a targeted enzyme of the type discussed below and in copending U.S. patent application Ser. Nos. 10/022,073 and 10/022,097, incorporated herein by reference in their entireties.

In another embodiment, the active moiety exhibits enzymatic activity, e.g., it is an enzyme or an active fragment or derivative of an enzyme. Of particular interest are enzymes that can be used to activate a prodrug in a therapeutic setting. A large number of enzymes with different catalytic modes of action have been used to activate prodrugs. See, e.g., Melton & Knox Enzyme-prodrug strategies for cancer therapy (1999) and Bagshawe et al., Curr Opin Immunol 11:579 (1999). Examples of types of enzymes that can be used to make the CABs of the present invention include, but are not limited to, proteases, carboxypeptidases, β-lactamases, asparaginases, oxidases, hydrolases, lyases, lipases, cellulases, amylases, aldolases, phosphatases, kinases, tranferases, polymerases, nucleases, nucleotidases, laccases, reductases, and the like. See, e.g., co-pending U.S. patent application Ser. No. 09/954,385, filed Sep. 12, 2001, incorporated herein by reference in its entirety. As such, CABs of the invention can, for example, exhibit protease, carboxypeptidase, β-lactamase, asparaginase, oxidase, hydrolase, lyase, lipase, cellulase, amylase, aldolase, phospatase, kinase, tranferase, polymerase, nuclease, nucleotidase, laccase or reductase activity or the like. Examples of enzymes that can be used are those that can activate a prodrug, discussed below, and those that can produce a toxic agent from a metabolite, e.g., hydrogen peroxide from glucose. See Christofidou-Solomidou et al, 2000, Am J Physiol Lung Cell Mol Physiol 278:L794.

In one embodiment, the present invention provides a CAB further comprising a lactamase (“BLA”). In another embodiment, the BLA is a targeted enzyme as described in co-pending U.S. patent application Ser. Nos. 10/022,073 and 10/022,097, incorporated herein by reference in their entirety.

BLA enzymes are widely distributed in both gram-negative and gram-positive bacteria. BLA sequences are well known. A representative example of a BLA sequence is depicted in FIG. 3. BLA enzymes vary in specificity, but have in common that they hydrolyze β-lactams, producing substituted β-amino acids. Thus, they confer resistance to antibiotics containing β-lactams. Because BLA enzymes are not endogenous to mammals, they are subject to minimal interference from inhibitors, enzyme substrates, or endogenous enzyme systems (unlike proteases), and therefore are particularly well-suited for therapeutic administration. BLA enzymes are further well-suited to the therapeutic methods of the present invention because of their small size (BLA from E. cloacae is a monomer of 39 kD; BLA from E. coli is a monomer of 30 kD) and because they have a high specific activity against their substrates and have optimal activity at 37° C. See Melton et al., Enzyme-Prodrug Strategies for Cancer Therapy, Kluwer Academic/Plenum Publishers, New York (1999).

Examples of specific BLAs that can be used to make the CABs of the present invention include, but are not limited to, Class A, B, C or D β-lactamase, β-galactosidase, see Benito et al., FEMS Microbiol. Lett. 123:107 (1994), fibronectin, glucose oxidase, glutathione S-transferase, see Napolitano et al., Chem. Biol. 3:359 (1996) and tissue plasminogen activator, see Smith et al., J. Biol. Chem. 270:30486 (1995). The β-lactamases have been divided into four classes based on their sequences. See Thomson et al., 2000, Microbes and Infection 2:1225-35. The serine β-lactamases are subdivided into three classes: A (penicillinases), C (cephalosporinases) and D (oxacillnases). Class B β-lactamases are the zinc-containing or metallo β-lactamases. Any class of BLA can be utilized to generate a CAB of the invention.

In one embodiment of the invention, the BLA has a specific activity greater than about 0.01 U/pmol against nitrocefin using the assay described in U.S. patent application Ser. No. 10/022,097. In another embodiment, the specific activity is greater than about 0.1 U/pmol. In another embodiment, the specific activity is greater than about 1 U/pmol. Preferably, these specific activities refer to the specific activity of the BLA when it is bound to a microtarget.

In one embodiment, the BLA enzyme in the CAB comprises the amino acid sequence set forth in SEQ ID NO:11. In another embodiment, the BLA enzyme in the CAB is at least 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% or more identical to the sequence depicted in FIG. 4.

In a preferred embodiment, the CAB is CAB1.11 or CAB1.11i.

The targets bound by the CAB, or one or more binding moieties, can be any substance or composition to which a molecule can be made to bind to CEA. In one embodiment, the target is a surface. In one embodiment, the surface is a biological surface. In another embodiment, the biological surface is a surface of an organ. In another embodiment, the biological surface is a surface of a tissue. In another embodiment, the biological surface is a surface of a cell. In another embodiment, the biological surface is a surface of a diseased organ, tissue or cell. In another embodiment, the biological surface is a surface of a normal or healthy organ, tissue or cell. In another embodiment, the surface is a macromolecule in the interstitial space of a tissue. In another embodiment, the biological surface is the surface of a virus or pathogen. In another embodiment, the surface is a non-biological surface. In another embodiment, the non-biological surface is a surface of a medical device. In another embodiment, the medical device is a therapeutic device. In another embodiment, the therapeutic device is an implanted therapeutic device. In another embodiment, the medical device is a diagnostic device. In another embodiment, the diagnostic device is a well or tray.

Sources of cells or tissues include human, all other animals, bacteria, fungi, viruses and plant. Tissues are complex targets and refer to a single cell type, a collection of cell types or an aggregate of cells generally of a particular kind. Tissue may be intact or modified. General classes of tissue in humans include but are not limited to epithelial tissue, connective tissue, nerve tissue and muscle tissue.

In another embodiment, the target is a cancer-related target that expresses CEA or that has CEA bound to itself or that has CEA located in its vicinity. The cancer-related target can be any target that a composition of the invention binds to as part of the diagnosis, detection or treatment of a cancer or cancer-associated condition in a subject, for example, a cancerous cell, tissue or organ, a molecule associated with a cancerous cell, tissue or organ, or a molecule, cell, tissue or organ that is associated with a cancerous cell, tissue or organ (e.g., a tumor-bound diagnostic or therapeutic molecule administered to a subject or to a biopsy taken from a subject, or a healthy tissue, such as vasculature, that is associated with cancerous tissue).

In a second aspect, the invention is drawn to a nucleic acid encoding a CAB molecule as set forth herein. The nucleic acid can be, for example, a DNA or an RNA. The present invention also provides a plasmid comprising a nucleic acid encoding a polypeptide comprising all or part of a CAB. The plasmid can be, for example, an expression plasmid that allows expression of the polypeptide in a host cell or organism, or in vitro. The expression vector can allow expression of the polypeptide in, for example, a bacterial cell. The bacterial cell can be, for example, an E. coli cell.

Because of the redundancy in the genetic code, typically a large number of DNA sequences encode any given amino acid sequence and are, in this sense, equivalent. As described below, it may be desirable to select one or another equivalent DNA sequences for use in an expression vector, based on the preferred codon usage of the host cell into which the expression vector will be inserted. The present invention is intended to encompass all DNA sequences that encode the desired CAB.

An operable expression clone may be used and is constructed by placing the coding sequence in operable linkage with a suitable control sequence in an expression vector. The vector can be designed to replicate autonomously in the host cell or to integrate into the chromosomal DNA of the host cell. The resulting clone is used to transform a suitable host, and the transformed host is cultured under conditions suitable for expression of the coding sequence. The expressed CAB is then isolated from the medium or from the cells, although recovery and purification of the CAB may not be necessary in some instances.

Construction of suitable clones containing the coding sequence and a suitable control sequence employ standard ligation and restriction techniques that are well understood in the art. In general, isolated plasmids, DNA sequences or synthesized oligonucleotides are cleaved, modified and religated in the form desired. Suitable restriction sites can, if not normally available, be added to the ends of the coding sequence so as to facilitate construction of an expression clone.

Site-specific DNA cleavage is performed by treating with a suitable restriction enzyme (or enzymes) under conditions that are generally understood in the art and specified by the manufacturers of commercially available restriction enzymes. See, e.g., product catalogs from Amersham (Arlington Heights, Ill.), Roche Molecular Biochemicals (Indianapolis, Ind.), and New England Biolabs (Beverly, Mass.). Incubation times of about one to two hours at a temperature that is optimal for the particular enzyme are typical. After each incubation, protein is removed by extraction with phenol and chloroform; this extraction can be followed by ether extraction and recovery of the DNA from aqueous fractions by precipitation with ethanol. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. See, e.g., Maxam et al., 1980, Methods in Enzymology 65:499-560.

Ligations can be performed, for example, in 15-30 μl volumes under the following standard conditions and temperatures: 20 mM Tris-Cl, pH 7.5, 10 mM MgCl₂, 10 mM DTT, 33 μg/ml BSA, 10-50 mM NaCl, and either 40 μM ATP and 0.01-0.02 (Weiss) units T4 DNA ligase at 0° C. (for ligation of fragments with complementary single-stranded ends) or 1 mM ATP and 0.3-0.6 units T4 DNA ligase at 14° C. (for “blunt end” ligation). Intermolecular ligations of fragments with complementary ends are usually performed at 33-100 μg/ml total DNA concentrations (5-100 nM total ends concentration). Intermolecular blunt end ligations (usually employing a 20-30 fold molar excess of linkers, optionally) are performed at 1 μM total ends concentration.

Correct ligations for plasmid construction can be confirmed using any suitable method known in the art. For example, correct ligations for plasmid construction can be confirmed by first transforming a suitable host, such as E. coli strain DG101 (ATCC 47043) or E. coli strain DG116 (ATCC 53606), with the ligation mixture. Successful transformants are selected by ampicillin, tetracycline or other antibiotic resistance or sensitivity or by using other markers, depending on the mode of plasmid construction, as is understood in the art. Plasmids from the transformants are then prepared according to the method of Clewell et al., 1969, Proc. Natl. Acad. Sci. USA 62:1159, optionally following chloramphenicol amplification. See Clewell, 1972, J. Bacteriol. 110:667. Alternatively, plasmid DNA can be prepared using the “Base-Acid” extraction method at page 11 of the Bethesda Research Laboratories publication Focus 5 (2), and very pure plasmid DNA can be obtained by replacing steps 12 through 17 of the protocol with CsCl/ethidium bromide ultracentrifugation of the DNA. As another alternative, a commercially available plasmid DNA isolation kit, e.g., HISPEED™, QIAFILTER™ and QIAGEN® plasmid DNA isolation kits (Qiagen, Valencia Calif.) can be employed following the protocols supplied by the vendor. The isolated DNA can be analyzed by, for example, restriction enzyme digestion and/or sequenced by the dideoxy method of Sanger et al., 1977, Proc. Natl. Acad. Sci. USA 74:5463, as further described by Messing et al., 1981, Nuc. Acids Res. 9:309, or by the method of Maxam et al., 1980, Methods in Enzymology 65:499.

The control sequences, expression vectors and transformation methods are dependent on the type of host cell used to express the gene. Generally, prokaryotic, yeast, insect or mammalian cells are used as hosts. Prokaryotic hosts are in general the most efficient and convenient for the production of recombinant proteins and are therefore preferred for the expression of the protein.

The prokaryote most frequently used to express recombinant proteins is E. coli. However, microbial strains other than E. coli can also be used, such as bacilli, for example Bacillus subtilis, various species of Pseudomonas and Salmonella, and other bacterial strains. In such prokaryotic systems, plasmid vectors that contain replication sites and control sequences derived from the host or a species compatible with the host are typically used.

For expression of constructions under control of most bacterial promoters, E. coliK12 strain MM294, obtained from the E. coli Genetic Stock Center under GCSC #6135, can be used as the host. For expression vectors with the P_(L)N_(RBS) or P_(L) T7_(RBS) control sequence, E. coli K12 strain MC1000 lambda lysogen, N₇N₅₃cI857 SusP₈₀, ATCC 39531, may be used. E. coli DG116, which was deposited with the ATCC (ATCC 53606) on Apr. 7, 1987, and E. coli KB2, which was deposited with the ATCC (ATCC 53075) on Mar. 29, 1985, are also useful host cells. For M13 phage recombinants, E. coli strains susceptible to phage infection, such as E. coli K12 strain DG98 (ATCC 39768), are employed. The DG98 strain was deposited with the ATCC on Jul. 13, 1984.

For example, E. coli is typically transformed using derivatives of pBR322, described by Bolivar et al., 1977, Gene 2:95. Plasmid pBR322 contains genes for ampicillin and tetracycline resistance. These drug resistance markers can be either retained or destroyed in constructing the desired vector and so help to detect the presence of a desired recombinant. Commonly used prokaryotic control sequences, i.e., a promoter for transcription initiation, optionally with an operator, along with a ribosome binding site sequence, include the β-lactamase (penicillinase) and lactose (lac) promoter systems, see Chang et al., 1977, Nature 198:1056, the tryptophan (trp) promoter system, see Goeddel et al., 1980, Nuc. Acids Res. 8:4057, and the lambda-derived P_(L) promoter, see Shimatake et al., 1981, Nature 292:128, and gene N ribosome binding site (N_(RBS)). A portable control system cassette is set forth in U.S. Pat. No. 4,711,845, issued Dec. 8, 1987. This cassette comprises a P_(L) promoter operably linked to the N_(RBS) in turn positioned upstream of a third DNA sequence having at least one restriction site that permits cleavage within six base pairs 3′ of the N_(RBS) sequence. Also useful is the phosphatase A (phoA) system described by Chang et al., in European Patent Publication No. 196,864, published Oct. 8, 1986. However, any available promoter system compatible with prokaryotes can be used to construct a expression vector of the invention.

In addition to bacteria, eukaryotic microbes, such as yeast, can also be used as recombinant host cells. Laboratory strains of Saccharomyces cerevisiae, Baker's yeast, are most often used, although a number of other strains are commonly available. While vectors employing the two micron origin of replication are common, see Broach, 1983, Meth. Enz. 101:307, other plasmid vectors suitable for yeast expression are known. See, e.g., Stinchcomb et al., 1979, Nature 282:39; Tschempe et al., 1980, Gene 10:157; and Clarke et al., 1983, Meth. Enz. 101:300. Control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes. See Hess et al., 1968, J. Adv. Enzyme Reg. 7:149; Holland et al., 1978, Biotechnology 17:4900; and Holland et al., 1981, J. Biol. Chem. 256:1385. Additional promoters known in the art include the promoter for 3-phosphoglycerate kinase, see Hitzeman et al., 1980, J. Biol. Chem. 255:2073, and those for other glycolytic enzymes, such as glyceraldehyde 3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase and glucokinase. Other promoters that have the additional advantage of transcription controlled by growth conditions are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism and enzymes responsible for maltose and galactose utilization.

Terminator sequences may also be used to enhance expression when placed at the 3′ end of the coding sequence. Such terminators are found in the 3′ untranslated region following the coding sequences in yeast-derived genes. Any vector containing a yeast-compatible promoter, origin of replication and other control sequences is suitable for use in constructing yeast expression vectors.

The coding sequence can also be expressed in eukaryotic host cell cultures derived from multicellular organisms. See, e.g., Tissue Culture, Academic Press, Cruz and Patterson, editors (1973). Useful host cell lines include COS-7, COS-A2, CV-1, murine cells such as murine myelomas N51 and VERO, HeLa cells and Chinese hamster ovary (CHO) cells. Expression vectors for such cells ordinarily include promoters and control sequences compatible with mammalian cells such as, for example, the commonly used early and late promoters from Simian Virus 40 (SV 40), see Fiers et al., 1978, Nature 273:113, or other viral promoters such as those derived from polyoma, adenovirus 2, bovine papilloma virus (BPV) or avian sarcoma viruses, or immunoglobulin promoters and heat shock promoters.

Enhancer regions are also important in optimizing expression; these are, generally, sequences found upstream of the promoter region. Origins of replication may be obtained, if needed, from viral sources. However, integration into the chromosome is a common mechanism for DNA replication in eukaryotes.

Plant cells can also be used as hosts, and control sequences compatible with plant cells, such as the nopaline synthase promoter and polyadenylation signal sequences, see Depicker et al., 1982, J. Mol. Appl. Gen. 1:561, are available. Expression systems employing insect cells utilizing the control systems provided by baculovirus vectors have also been described. See Miller et al., in Genetic Engineering (1986), Setlow et al., eds., Plenum Publishing, Vol. 8, pp. 277-97. Insect cell-based expression can be accomplished in Spodoptera frugipeida. These systems are also successful in producing recombinant enzymes.

Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described by Cohen, 1972, Proc. Natl. Acad. Sci. USA 69:2110, is used for prokaryotes or other cells that contain substantial cell wall barriers. Infection with Agrobacterium tumefaciens, see Shaw et al., 1983, Gene 23:315, is used for certain plant cells. For mammalian cells, the calcium phosphate precipitation method of Graham et al., 1978, Virology 52:546 is preferred. Transformations into yeast are carried out according to the method of Van Solingen et al., 1977, J. Bact. 130:946, and Hsiao et al., 1979, Proc. Natl. Acad. Sci. USA 76:3829.

It may be desirable to modify the sequence of a DNA encoding a polypeptide comprising all or part of a CAB of the invention to provide, for example, a sequence more compatible with the codon usage of the host cell without modifying the amino acid sequence of the encoded protein. Such modifications to the initial 5-6 codons may improve expression efficiency. DNA sequences which have been modified to improve expression efficiency, but which encode the same amino acid sequence, are considered to be equivalent and encompassed by the present invention.

A variety of site-specific primer-directed mutagenesis methods are available and well-known in the art. See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, 1989, second edition, chapter 15.51, “Oligonucleotide-mediated mutagenesis,” which is incorporated herein by reference. The polymerase chain reaction (PCR) can be used to perform site-specific mutagenesis. In another technique now standard in the art, a synthetic oligonucleotide encoding the desired mutation is used as a primer to direct synthesis of a complementary nucleic acid sequence contained in a single-stranded vector, such as pBSM13+ derivatives, that serves as a template for construction of the extension product of the mutagenizing primer. The mutagenized DNA is transformed into a host bacterium, and cultures of the transformed bacteria are plated and identified. The identification of modified vectors may involve transfer of the DNA of selected transformants to a nitrocellulose filter or other membrane and the “lifts” hybridized with kinased synthetic mutagenic primer at a temperature that permits hybridization of an exact match to the modified sequence but prevents hybridization with the original unmutagenized strand. Transformants that contain DNA that hybridizes with the probe are then cultured (the sequence of the DNA is generally confirmed by sequence analysis) and serve as a reservoir of the modified DNA.

Once the polypeptide has been expressed in a recombinant host cell, purification of the polypeptide may be desired. A variety of purification procedures can be used.

In another embodiment, a nucleic acid encoding the CAB hybridizes to a nucleic acid complementary to a nucleic acid encoding any of the amino acid sequences disclosed herein under highly stringent conditions. The highly stringent conditions can be, for example, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C. and washing in 0.1×SSC/0.1% SDS at 68° C. (Ausubel et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & Sons, Inc., New York, at p. 2.10.3). Other highly stringent conditions can be found in, for example, Current Protocols in Molecular Biology, at pages 2.10.1-16 and Molecular Cloning: A Laboratory Manual, 2d ed., Sambrook et al. (eds.), Cold Spring Harbor Laboratory Press, 1989, pages 9.47-57. In another embodiment, moderately stringent conditions are used. The moderately stringent conditions can be, for example, washing in 0.2×SSC/0.1% SDS at 42° C. (Ausubel et al., 1989, supra). Other moderately stringent conditions can be found in, for example, Current Protocols in Molecular Biology, Vol. I, Ausubel et al. (eds.), Green Publishing Associates, Inc., and John Wiley & Sons, Inc., 1989, pages 2.10.1-16 and Molecular Cloning: A Laboratory Manual, 2d ed., Sambrook et al. (eds.), Cold Spring Harbor Laboratory Press, 1989, pages* 9.47-57.

In a third aspect the present invention provides a method of treating a subject in need thereof comprising administering to a subject a CAB and a prodrug that is a substrate of the CAB. In another embodiment, the invention provides a method of treating a subject by administering to the subject a CAB, further comprising a BLA, and a prodrug that is converted by the BLA into an active drug. In another embodiment, the CAB is specifically CAB1.11 or CAB1.11i.

Melphalan derivatives are especially suitable as the prodrug for this embodiment of the invention. Examples of enzyme/prodrug/active drug combinations can be found in, e.g., Senter et al., U.S. Pat. No. 5,773,435, which is incorporated by reference herein, including any drawings. Other examples of suitable prodrugs for this embodiment are provided in, e.g., Melton et al., Enzyme-Prodrug Strategies for Cancer Therapy, Kluwer Academic/Plenum Publishers, New York (1999), Bagshawe et al., Current Opinion in Immunology 11:579-83 (1999) and Kerr et al., Bioconjugate Chem. 9:255-59 (1998). Wilman, “Prodrugs In Cancer Chemotherapy,” Biochemical Society Transactions, 14, pp. 375-82 (615th Meeting, Belfast 1986) and V. J. Stella et al., “Prodrugs: A Chemical Approach To Targeted Drug Delivery,” Directed Drug Delivery, R. Borchardt et al. (ed), pp. 247-67 (Humana Press 1985).

In one embodiment, the prodrug is a peptide. Examples of peptides as prodrugs can be found in Trouet et al, Proc Natl Acad Sci USA 79:626 (1982), and Umemoto et al., Int J Cancer 43:677 (1989). These and other reports show that peptides are sufficiently stable in blood. Another advantage of peptide-derived prodrugs is their amino acid sequences can be chosen to confer suitable pharmacological properties like half-life, tissue distribution and low toxicity to the active drugs. Most reports of peptide-derived prodrugs relied on relatively nonspecific activation of the prodrug by, for instance, lysosomal enzymes.

The prodrug can be one that is converted to an active drug in more than one step. For example, the prodrug can be converted to a precursor of an active drug by the CAB. The precursor can be converted into the active drug by, for example, the catalytic activity of one or more additional CABs, the catalytic activities of one or more other enzymes administered to the subject, the catalytic activity of one or more enzymes naturally present in the subject or at the target site in the subject (e.g., a protease, a phosphatase, a kinase or a polymerase), by a drug that is administered to the subject or by a chemical process that is not enzymatically catalyzed (e.g., oxidation, hydrolysis, isomerization or epimerization).

Most studies involving prodrugs are generated after programs with existing drugs are found to be problematic. In particular anticancer drugs were generally characterized by a very low therapeutic index. By converting these drugs into prodrugs with reduced toxicity and then selectively activating them in the diseased tissue, the therapeutic index of the drug was significantly increased. See, e.g., Melton et al., Enzyme-prodrug strategies for cancer therapy (1999), and Niculescu-Duvaz et al., Anticancer Drug Des 14:517 (1999).

The literature describes many methods to alter the substrate specificity of enzymes by protein engineering or directed evolution. Thus one skilled in the art is able to evolve the specificity of an enzyme to accommodate even structures that would be poor substrates for naturally-occurring enzymes. Accordingly, prodrugs can be designed even though the drugs were otherwise not amenable to a prodrug strategy.

The prodrugs of the invention can include, but are not limited to, auristatins, camptothecins, phosphate-containing prodrugs, thiophosphate-containing prodrugs, sulfate-containing prodrugs, peptide-containing prodrugs, D-amino acid-modified prodrugs, glycosylated prodrugs, β-lactam-containing prodrugs, optionally substituted phenoxyacetamide-containing prodrugs or optionally substituted phenylacetamide-containing prodrugs, 5-fluorocytosine and other 5-fluorouridine prodrugs which can be converted by the enzyme of the conjugate into the more active cytotoxic free drug. Examples of cytotoxic drugs that can be derivatized into a prodrug form for use in this invention include, but are not limited to, etoposide, temposide, adriamycin, daunomycin, caminomycin, aminopterin, dactinomycin, mitomycins, cis-platinum and cis-platinum analogues, bleomycins, esperamicins (see U.S. Pat. No. 4,675,187), 5-fluorouracil, melphalan, other related nitrogen mustards and derivatives thereof. (See, e.g., U.S. Pat. No. 4,975,278).

In one embodiment of the invention, the CAB comprises an alkaline phosphatase (AP) that converts a 4′-phosphate derivative of the epipodophyl-lotoxin glucosides into an active anti-cancer drug. Such derivatives include etoposide-4′-phosphate, etoposide-4′-thiophosphate and teniposide-4′-phosphate. Other embodiments of the invention may include phosphate derivatives of these glucosides wherein the phosphate moiety is placed at other hydroxyl groups on the glucosides. According to another embodiment, however, the L5 phosphate derivative used as a pro-drug in this invention is etoposide-4′-phosphate or etoposide-4′-thiophosphate. The targeted AP removes the phosphate group from the prodrug, releasing an active antitumor agent. The mitomycin phosphate prodrug of this embodiment may be an N⁷-C₁₋₈ alkyl phosphate derivative of mitomycin C or porfiromycin or pharmaceutically acceptable salts thereof. N⁷ refers to the nitrogen atom attached to the 7-position of the mitosane nucleus of the parent drug. According to another embodiment, the derivative used is 7-(2′-aminoethylphosphate)mitomycin (“MOP”). Alternatively, the MOP compound may be termed, 9-methoxy-7-[[(phos-phonooxy)ethyl]amino]mitosane disodium salt. Other embodiments of the invention may include the use pf N⁷-alkyl mitomycin phosphorothioates as prodrugs.

In still another embodiment of the invention, the CAB comprises a penicillin amidase enzyme that converts a novel adriamycin prodrug into the active antitumor drug adriamycin. In another embodiment, the penicillin amidase is a penicillin V amidase (“PVA”) isolated from Fusarium oxysporum that hydrolyzes phenoxyacetyl amide bonds. The prodrug utilized can be N-(p-hydroxyphenoxyacetyl)adriamycin (“APO”), which is hydrolyzed by the amidase to release the potent antitumor agent or adriamycin.

The present invention also comprises, for example, the use of the adriamycin prodrug, N-(p-hydroxyphenoxyacetyl)adriamycin and other related adriamycin prodrugs that can be derivatized in substantially the same manner. For example, use of the prodrug N-(phenoxyacetyl) adriamycin is also within the scope of the invention. In addition, it is to be understood that the adriamycin prodrugs of this invention include other N-hydroxyphenoxyacetyl derivatives of adriamycin, e.g., substituted at different positions of the phenyl ring, as well as N-phenoxyacetyl derivatives containing substituents on the phenyl ring other than the hydroxyl group described herein.

Furthermore, the present embodiment encompasses the use of other amidases, such as penicillin G amidase, as part of the CAB as well as other prodrugs correspondingly derivatized such that the particular amidase can hydrolyze that prodrug to an active antitumor form. For example, when the CAB further comprises penicillin G amidase, the prodrug should contain a phenylacetylamide group (as opposed to the phenoxyacetylamide group of APO) because penicillin G amidases hydrolyze this type of amide bond (see, e.g., A. L. Margolin et al., Biochim. Biophys Acta. 616, pp. 283-89 (1980)). Thus, other prodrugs of the invention include N-(p-hydroxyphenylacetyl) adriamycin, N-(phenylacetyl) adriamycin and other optionally substituted N-phenylacetyl derivatives of adriamycin.

It should also be understood that the present invention includes any prodrug derived by reacting the amine group of the parent drug with the carboxyl group of phenoxyacetic acid, phenylacetic acid or other related acids. Thus, prodrugs of anthracyclines other than adriamycin that are capable of being derivatized and acting in substantially the same manner as the adriamycin prodrugs described herein falls within the scope of this invention. For example, other prodrugs that can be produced and used in accordance with this invention include hydroxyphenoxyacetylamide derivatives, hydroxyphenylacetylamide derivatives, phenoxyacetylamide derivatives and phenylacetylamide derivatives of anthracyclines such as daunomycin and caminomycin. Other amine-containing drugs such Zs as melphalan, mitomycin, aminopterin, bleomycin and dactinomycin can also be modified described herein to yield prodrugs of the invention.

Another embodiment of the invention involves a CAB form of the enzyme cytosine deaminase (“CD”). The deaminase enzyme catalyzes the conversion of 5-fluorocytosine (“5-FC”), a compound lacking in antineoplastic activity, to the potent antitumor drug, 5-fluorouracil (“5-FU”).

Another embodiment of the method of this invention provides a method of combination chemotherapy using several prodrugs and a single CAB. According to this embodiment, a number of prodrugs are used that are all substrates for the same CAB. Thus, a particular CAB converts a number of prodrugs into cytotoxic form, resulting in increased antitumor activity at the tumor site.

There is often a requirement for extending the blood circulation half-lives of pharmaceutical peptides, proteins, or small molecules. Typically short half-lives—lasting minutes to hours—require not only frequent, but also high doses for therapeutic effect—often so high that initial peak doses cause side effects. Extending the half-life of such therapeutics permits lower, less frequent, and therefore potentially safer doses, which are cheaper to produce. Previously researchers have increased protein half-life by fusing them covalently to PEG, see U.S. Pat. No. 5,711,944, human blood serum albumin, see U.S. Pat. No. 5,766,883, or Fc fragments, see WO 00/24782. In addition, nonspecific targeting of drugs to human serum albumin has been accomplished by chemical coupling drugs in vivo. See U.S. Pat. No. 5,843,440. Furthermore, in the case of cancer drugs it has been proposed that high molecular weight drugs may localize in tumors due to enhanced permeability and is retention. Therefore, improvement in the therapeutic index of a drug can be obtained by linking the drug to a protein or other high molecular weight polymer.

In another embodiment the present invention provides a method of treating a condition in a subject in need thereof, comprising administering to the subject a CAB with β-lactamase activity and a prodrug. In one embodiment, the subject in need thereof is a cancer patient. In another embodiment, the CAB is targeted to a CEA expressing cell, tissue, tumor or organ. In another embodiment, the prodrug is converted by the CAB into an active drug. In another embodiment, the active drug is an alkylating agent. In another embodiment, the prodrug is an anticancer nitrogen mustard prodrug. In another embodiment, the active drug is melphalan. In another embodiment, the prodrug is C-Mel. In another embodiment, the prodrug is glutaryl-C-Mel or glutaryl-C-Mel-L-Phe-NH2 (see, for example, Senter et al, U.S. Pat. No. 5,773,435, which is incorporated by reference herein, including any drawings and Kerr et al., Bioconjugate Chem. 9:255-59 (1998)). In another embodiment, the prodrug is vinca-cephalosporin or doxorubicin cephalosporin. See Bagshawe et al., Current Opinion in Immunology, 11:579-83 (1999). Other prodrug/enzyme combinations that can be used in the present invention include, but are not limited to, those found in U.S. Pat. No. 4,975,278 and Melton et al., Enzyme-Prodrug Strategies for Cancer Therapy Kluwer Academic/Plenum Publishers, New York (1999).

In a fourth aspect, the invention is drawn to a pharmaceutical composition comprising a CAB molecule. The CABs, nucleic acids encoding them and, in certain embodiments, prodrugs described herein can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the active compound and a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

The invention includes methods for preparing pharmaceutical compositions for modulating the expression or activity of a CAB, prodrug or nucleic acid of interest. Such methods comprise formulating a pharmaceutically acceptable carrier with an agent that modulates expression or activity of an active compound of interest. Such compositions can further include additional active agents. Thus, the invention further includes methods for preparing a pharmaceutical composition by formulating a pharmaceutically acceptable carrier with an agent that modulates expression or activity of a CAB, prodrug or nucleic acid of interest and one or more additional active compounds.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g, inhalation), transdermal (topical), transmucosal and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include normal saline, Water for Injection, 5% dextrose or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like) and suitable mixtures thereof. The proper fluidity can be maintained by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.

Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation is freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches or capsules.

Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressurized container or dispenser that contains a suitable propellant, e.g., a gas such as carbon dioxide or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

In one embodiment, the formulation comprises sulfobutylether-7-beta-cyclodextrin and 2-hydroxypropyl-β-cyclodextrin, as disclosed, for example, in U.S. Pat. No. 6,216,375 and U.S. Pat. No. 6,537,988, each of which are incorporated by reference, herein, including any drawings.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

Typically, the amount of CAB to be delivered to a subject will depend on a number of factors, including, for example, the route of administration, the activity of the CAB, the degree to which it is specifically targeted to the desired cells, tissues or organs of the subject, the length of time required to clear the non-specifically bound CAB from the subject, the desired therapeutic effect, the body mass of the subject, the age of the subject, the general health of the subject, the sex of the subject, the diet of the subject, the subject's immune response to the CAB, other medications or treatments being administered to the subject, the severity of the disease and the previous or future anticipated course of treatment.

For applications in which a prodrug also is administered, other factors affecting the determination of a therapeutically effective dose will include, for example, the amount of prodrug administered, the activity of the prodrug and its corresponding active drug and the side effects or toxicities of the prodrug and the active drug.

Examples of ranges of mass of CAB/mass of subject include, for example, from about 0.001 to 30 mg/kg body weight, from about 0.01 to 25 mg/kg body weight, from about 0.1 to 20 mg/kg body weight, and from about 1 to 10 mg/kg, 2 to 9 mg/kg, 3 to 8 mg/kg, 4 to 7 mg/kg, or 5 to 6 mg/kg body weight.

In a particular example, a subject is treated with a CAB in the range of between about 0.1 to 20 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, preferably between about 3 to 7 weeks and preferably for about 4, 5, or 6 weeks. It will also be appreciated that the effective dosage of CAB may increase or decrease over the course of a particular treatment, and that the treatment will continue, with or without modification, until a desired result is achieved or until the treatment is discontinued for another reason. Changes in dosage may result and become apparent from the results of diagnostic assays as described herein.

It is understood that appropriate doses of prodrugs depend upon a number of factors within the ken of the ordinarily skilled physician, veterinarian or researcher. The dose(s) of the prodrug will depend, for example, on the same factors provided above as factors affecting the effective dose of the CAB. Exemplary doses include milligram or microgram amounts of the prodrug per kilogram of subject or sample weight (e.g., about 1 microgram per kilogram to about 500 milligrams per kilogram, about 100 micrograms per kilogram to about 5 milligrams per kilogram or about 1 microgram per kilogram to about 50 micrograms per kilogram). It is furthermore understood that appropriate doses of a prodrug depend upon the potency of the prodrug with respect to the desired therapeutic effect. When one or more of these prodrugs is to be administered to an animal (e.g., a human), a physician, veterinarian or researcher may, for example, prescribe a relatively low dose at first, subsequently increasing the dose until an appropriate response is obtained.

Preferably, the CAB is administered to the subject, then the prodrug is administered. More preferably, the time between the administration of the CAB and administration of the prodrug is sufficient to allow the CAB to accumulate at its target site by binding to its target, and to allow unbound CAB to be cleared from the non-targeted portions of the subject's body. Most preferably, the ratio of target-bound CAB to unbound CAB in the subject's body will be at or near its maximum when the prodrug is administered. The time necessary after administration of the CAB to reach this point is called the clearing time. The clearing time can be determined or approximated in an experimental system by, for example, administering a detectable CAB (e.g., a radiolabeled or fluorescently labeled CAB) to a subject and simultaneously measuring the amount of enzyme at the target site and at a non-targeted control site at timed intervals. For some prodrugs, particularly those whose counterpart active drugs are highly toxic, it may be more important to ensure that the levels of unbound CAB in the subject's system are below a certain threshold. This too can be determined experimentally, as described above.

In one embodiment, administration of the prodrug is systemic. In another embodiment, administration of the prodrug is at or near the target.

The pharmaceutical compositions can be included in a container, pack, dispenser or kit together with instructions for administration.

EXAMPLES Example 1 Construction of CAB1.10

The amino acid sequence of the scFv portion of CAB1.10 molecule was derived from murine anti-CEA monoclonal antibody (MAb) T84.66 sequence (Neumaier et. al., (1990) Cancer Research 50:2128-2134). The nucleotide sequence of the synthetic gene was designed based on E. coli codon usage plus a 30-aa linker connecting vL and vH domains with the following genetic configuration: vL-(GGGGS)₆-vH. A 968-bp DNA fragment containing the designed gene was synthesized by DNA2.0 (Menlo Park, Calif.) with flanking NcoI and EcoRV restriction sites and cloned into their pDriveCloningVector resulting in plasmid pG00229.

Plasmid pNA31.1 is a stuffer vector with an inactive BLA gene that was used to clone the scFv portion from plasmid pG00229. This was derived from plasmid pME27.1 (see WIPO publication WO03105757A2, which is incorporated by reference, herein, including any drawings) upon digestion with PstI enzyme to remove the 461-bp region containing a large part of the exigent antibody and a small part of BLA followed by self-ligation.

Upon digestion of plasmids pG00229 and pNA31.1 with NcoI and EcoRV enzymes, a 0.9-kb insert fragment and a 4.3-kb vector fragment, respectively, were gel purified. They were then ligated, followed by transformation into E. coli TOP10F′ (Invitrogen, Carlsbad, Calif.) competent cells and selection on agar plates containing Luria-Bertani medium and 5 ppm chloramphenicol (cmp) and 0.1 ppm cephotaxim (CTX). Out of hundreds of colonies, six clones were checked for proper size and orientation of the scFv fragment by isolating plasmid DNAs and digesting them with EcoRI and SacI enzymes. With both enzymes, expected restriction patterns were observed for all six clones tested. After testing four of them for expression and binding, plasmid pHR03.1 was selected for further engineering and named as CAB1.10 molecule harboring plasmid.

Example 2 Combinatorial Consensus Mutagenesis of CAB1.10

To improve the expression of CAB1.10 protein, a combinatorial consensus mutagenesis CCM approach as described before (see Attorney Docket Number 816P, which is incorporated by reference in its entirety, including any drawings) was pursued by targeting 35 amino acid residues in the frame work regions of vL and vH domains using plasmid pHR03.1 as a template. These 35 residues (14 positions in vH and 21 positions in vL) were identified as being significantly different (<10% abundance) compared to a typical human antibody sequence. Using a modified version of Multi-site Quikchange Mutagenesis (Stratagene, Calif.) protocol as described before (see Attorney Docket Number 816P, which is incorporated by reference herein, including any drawings), CCM libraries HR12 and HR14 with combined primer concentrations of 2 uM and 0.4 uM, respectively, were constructed employing 35 phosphorylated primers as shown in table 1. After mutagenesis and DpnI digestion, 2.5 ul out of 25 ul PCR reaction mix was transformed into E. coli TOP 10F′ cells followed by selection on agar plates containing Luria-Bertani medium and 5 ppm chloramphenicol (cmp) and 0.1 ppm cephotaxim (CTX). 100 clones from library HR12 and 200 clones from library HR14 were initially screened for improved expression in 96-well microtiter plates as described below resulting in the selection of clone HR14.8. Sequencing of this clone revealed that it recruited A12S and R72G mutations in the vL region of the scFv fragment. Complete sequencing of the entire fusion gene of clone HR14.8 revealed no additional mutations elsewhere in the gene. This clone HR14.8 (encoded and was named) the CAB1.11 molecule.

TABLE 1 Sequence of primers used for combinatorial con- sensus mutagenesis (CCM) of CAB1.10 protein. Primer name corresponds to the amino acid to be changed in the light (L) or heavy (H) chain, its position, and the intended mutation (mutated codon shown in upper case). So, for example, LD1Q corresponds to Asp (D) at position 1 of the light (L) chain to be changed to Gln (Q). The numbering starts with the first residue of either light or heavy chains. All primers were designed to the sense strand. The LA12S and LR68G primers incorporate A12S and R72G mutations in the CAB1.11 protein, respectively, and are shown in bold. Combinatorial Consensus Mutagenesis (CCM) Primers Name Sequence (5′-3′) Length LD1Q CcggccatggccCAGatcgtcctgacccagagcccg 36 LI2S GccatggccgacTCTgtcctgacccagagcccggca 38 ag LS7P GtcctgacccagCCGccggcaagcctggctgtttcc 36 LA9S AcccagagcccgTCTagcctggctgtttccctgggc 36 LA12S CcggcaagcctgTCTgtttccctgggccagcgtgcc 36 LM21I CcagcgtgccactATCtcctgcagagcgggtgagtc 36 LP43A GaaaccgggtcagGCGccaaaactgctgatctatcg 36 LV60D GtccggcatcccgGACcgtttctccggtactggctc 36 LT65S GtacgtttctccggtTCTggctctcgtactgatttt 39 acc LG66K CgtttctccggtactAAAtctcgtactgattttacc 39 ctg LR68G CcggtactggctctGGTactgattttaccctgatta 38 tc LD70T CtggctctcgtactACCtttaccctgattatcgacc 38 cg LF71A GgctctcgtactgatGCGaccctgattatcgacccg 39 gtg L174T ActgattttaccctgACCatcgacccggtggaagca 39 gac LD76S TtaccctgattatcTCTccggtggaagcagacgatg 39 ttg LP77G AccctgattatcgacGGTgtggaagcagacgatgtt 39 gcc LV83E GtggaagcagacgatGAAgccacctactattgccag 39 cag LT85D GcagacgatgttgccGACtactattgccagcagacc 39 aac LE105T CggtactaaactgACCatcaaaggcggtggtggttc 39 tgg LI106V TactaaactggagGTTaaaggcggtggtggttctgg 39 tgg LK106aL TaaactggagatcCTGggcggtggtggttctggtgg 39 tgg HE13K GgtgcggagctcgttAAAccgggcgcttctgtgaaa 39 ctg HN28T ActgcatctggtttcACCattaaggacacctacatg 39 cac HI29F GcatctggtttcaacTTCaaggacacctacatgcac 39 tgg HK30S TctggtttcaacattTCTgacacctacatgcactgg 39 gtg HK38R TacatgcactgggtgAGAcaacgcccggaacagggt 39 ctg HR40A CactgggtgaaacaaGCGccggaacagggtctggag 39 tgg HE42G TgaaacaacgcccgGGTcagggtctggagtggatcg 39 gtc HK66R CcaaaattccagggtAGAgcaaccatcactgctgat 39 acc HA67F AaattccagggtaaaTTCaccatcactgctgatacc 39 tcc HS75K CtgctgatacctccAAAaacactgcttacctgcagc 40 tgac HT82aN GcttacctgcagctgAACtccctgactagcgaagac 39 acc HP94R TttattactgcgctAGAttcggctactatgtcagcg 41 attac HF95G TattactgcgctccgGGTggctactatgtcagcgat 39 tac HS108L TggggtcagggcaccCTGgttaccgtttctagcaca 39 ccg

Example 3 Screening of the HR14 Library

Library pHR14 was plated onto agar plates containing LB medium and 5 mg/l chloramphenicol and 0.1 mg/l cephotaxime (CTX, Sigma). Colonies from each library and parent colonies were transferred into 96 well plates containing 100 ul LB+5 ppm cmp. Plates were incubated at 30 C in a humidified box with shaking for 48-72 hrs. On the day of screening, 100 ul of B-Per reagent (PIERCE) was added into each well and shaken at room temperature for 30 min.

Target protein CEA (Biodesign International) was immobilized in a 96 well polystyrene plate by adding 100 of 5 ug/ml CEA in 50 mM NaHCO3 and the plate was incubated at 4 C overnight. The plate was then washed with PBST (PBS+0.1% Tween 20) and blocked with 300 ul/well of 1% Casein in PBS for 2 hours at room temp. On the day of screening, the plate was washed with PBST, subsequently, 80 ul/well of PBSO (PBS+0.125% Octylglucopyranoside) was first added into the plate, followed by 20 ul of diluted B-Per extracted cell culture of each well from expression plate. The plate was incubated at room temperature with gentle shaking for 1 hour. After 1 hour, the plate was washed with PBST, 200 ul of BLA substrate (nitrocefin in PBSO) was added into each well, the bound CAB molecule was measured by monitoring hydrolysis of nitrocefin at wavelength 490 nm.

Seven variants of interest from the primary screening were streaked out on LA+5 ppm cmp agar plate. Colonies from each variant were inoculated in 5 ml of LB+5 ppm cmp. The tubes were incubated at 25 C for 70 hours. The culture was pelleted and resuspended in B-Per reagent. Target protein CEA was immobilized in 96 well polystyrene plate at 5 ug/ml of 100 ul/well, the plate was then blocked with 1% Casein. On the day of screening, 80 ul/well of PBS buffer pH7.1 was added into target plate, and 20 ul/well of 2-fold serial diluted B-Per extract was added to the target plate. The plates were incubated at room temperature for 1 hour and were then washed with PBST. 200 ul of BLA substrate nitrocefin in PBSO was added into each well, the bound CAB molecules was measured by monitoring hydrolysis of nitrocefin at wavelength 490 nm. Assay results are shown in FIG. 6. The best variant, HR14.8 was chosen for further refinement.

Example 4 Epitope Removal of BLA

The i-mune assay was performed on the sequence for beta-lactamase as described (U.S. patent application Ser. No. 09/060,872, filed Apr. 15, 1998). Human population-based identification of CD4+ T cell peptide epitope determinants. (Journal of Immunological Methods, 281:95-108). Community donor peripheral blood cell samples were used. Four CD4+ T cell epitopes were identified. For each epitope peptide sequence, critical residue testing was performed. Critical residue testing included both an alanine scan of the peptide sequences, as well as specific amino acid modifications guided by functional and structural constraints. Peptide epitope sequences that reduced the level of proliferation to background levels were chosen and incorporated into a DNA construct of the beta-lactamase enzyme sequence. Modified enzyme protein variants were expressed and purified, then tested for their ability to induce cellular proliferation using human peripheral blood cells in vitro. The variant that induced the lowest level of cellular proliferation in vitro (which included BLA-epitope removing mutations at sites K21A and S324A) was selected for inclusion in CAB1.11i, as described below.

Example 5 Construction of CAB1.11i

Plasmid pHR19.2 was constructed from template HR14.8 (CAB1.11) by the Multi-site Quikchange Mutagenesis protocol (Stratagene, Calif.) to recruit the BLA-epitope-removing mutations K21A and S324A in the BLA protein. Using phosphorylated primers HR016F and HR017F (HR016F: 5′-[Phosp]GATTACCCCGCTGATGGCGGCCCAGTCTGTTCCAG-3′; HR017F: 5′-[Phosp]CTACTGGCGGGTTTGGCGCGTACGTGGCCTTTATTCCTG-3′) for recruiting mutations K21A and S324A, respectively, a multi-site Quikchange mutagenesis (Stratagene, Calif.) reaction was performed followed by digestion with DpnI enzyme. 2.5 ul out of 2.5 ul PCR product was transformed into E. coli TOP10F′ competent cells followed by selection of transformants on LA+Cm5+0.1 CTX plates. Plasmid DNAs from 16 clones were isolated and sequenced to confirm the recruitment of both mutations into the same plasmid. Only 2 (pHR19.2 and pHR19.15) clones were found to have both mutations in the same plasmid. Complete sequencing of the entire fusion gene of plasmid pHR19.2 revealed no additional mutations elsewhere in the gene. Finally, plasmid pHR19.2 was selected as the molecule that encodes the CAB1.11i molecule.

Example 6 Expression of CAB1.11i

E Coli. strain EB101.1 was obtained as a random isolate of strain NL106. Strain NL106 was transformed with a plasmid directing the production of an ADEPT construct and cultured in a 14 liter fermentor. Isolates from the fermetor were tested in shake flasks for production of lactamase activity, and one isolate NL106EB was chosen as host. Strain NL106 was subjected to serial shake flask cultures in defined medium and a faster growing strain, EB101.1, was isolated.

One glycerol vial containing strain EB101.1 carrying plasmid pHR19.2 was used to inoculate a flask containing 600 ml of MDM+1% Glucose media, the ingredients being shown in Table 2. The flask was incubated at 30 C and 150 rpm in an incubator shaker. The growth was monitored by sampling flask and measuring Absorbance at A550. When the broth reached a reading of approximately A550=1, the content of the flask was transferred to a seed fermenter containing the same medium. When the broth inside the seed fermenter reached a cell density of A550=7-8, then 600 ml was transferred to the production fermenter containing production medium as shown in Table 2. The production fermenter was pH controlled and fed a 60% Glucose solution. The production fermenter was allowed to run for 32-40 h until the amount of CAB1.11i reached its maximum. Typical production profiles are shown in FIG. 7, where lactamase activity is measured in in mg/ml.

TABLE 2 MDM + 1% Glucose Medium (Flask and Seed Tank medium) Ingredient Concentration in g/L K2HPO4 13.6 KH2PO4 13.6 MgSO4*7H2O 2 Citric Acid Monohydrate 2 Ferric Ammonium Citrate 0.3 (NH4)2SO4 3.2 Monosodium Glutamate 3.75 or L-Serine at 2.11 g/L L-Tryptophan 0.40 Trace Metal Solution 1 ml Glucose 10

TABLE 3 Production Medium Ingredient Concentration in g/L Calcium chloride dihydrate 0.1818 Monosodium Glutamate 3.75 or L-Serine at 2.11 g/L L-Tryptophan 0.40 Potassium phosphate monobasic 13.63 Citric Acid monohydrate 1.818 Magnesium sulfate heptahydrate 1.82 Ferric Ammonium citrate 0.303 Trace Metal Solution 0.909 Mazu DF204 0.78 Glucose 10 Sulfuric Acid As required to adjust pH to 7.0 Ammonium Hydroxide To control the pH at 7.0 during the fermentation

Example 7 Purification of CAB1.11i

Preparation of high purity samples of CAB1.11i was achieved using the process outlined in FIG. 8. This process was highly efficient as the end product at each step can be input into the next step without the need for pH adjustment, buffer exchange or salt removal.

Step 1: B-PER Cell Wall Disruption and 60% Ammonium Sulfate Cut

Add 2.5 ml B-PER Reagent (in Phosphate Buffer, Pierce Biotechnology Inc., product #78266) per gram of frozen E. coli cell paste. Benzonase Nuclease (Novagen, product #70664-3) is also added at a dilution of 1:1000 during this step to hydrolyze DNA. Mixture is stirred vigorously for 60 minutes at Room temperature.

Remove cell debris by centrifugation at 4° C. for 20 minutes and 12,000 rpm. Discard pellet.

Add 390 grams solid ammonium sulfate (Sigma, product# A-2939) per 1 liter of supernatant to achieve 60% saturation at 25° C. Stir 40 minutes at room temperature. Recover precipitated protein by centrifugation at 4° C. for 20 minutes and 12,000 rpm. Solubilize pellet into TEA Buffer (20 mM triethanolamine/0.5M NACl, pH 7). The crude protein solution should be centrifuged at 14,000 rpm and filtered through a 0.22 μm filter prior to loading onto the PBA column.

Step 2: CAB1.11i Protein Capture via PBA Affinity Chromatography

A 30 ml PBA column (m-Aminophenylboronic acid immobilized onto agarose beads from Sigma, product # A-8530) was ‘cleaned’ with 150 ml borate buffer (0.5M borate/0.5M NaCl, pH7), and equilibrated with 150 ml TEA buffer prior to loading crude protein. After loading sample, the column was washed with 150 ml TEA buffer (5 column volumes).

After loading the sample, the column is washed with 150 ml TEA buffer.

CAB protein is eluted with 150 ml borate buffer and collected in 10 ml fractions. Eluted fractions are assayed for β-lactamase using the nitrocefin plate assay, described, for example, in WO 0247717A2.

Step 3: Removal of CAB Degradation Products via Hydrophobic Charge Induction

Chromatography 5 ml of CAB protein eluted from the PBA column loaded directly onto a 7 ml MEP HyperCel column (produced by BioSepra) equilibrated in phosphate buffered saline (PBS). After loading the sample, the column was washed with 10 column volumes of PBS. CAB protein was eluted from the resin using a 10 column volume gradient elution with 75 mM sodium citrate buffer at pH 5.2.

Eluted fractions assayed for β-lactamase using the nitrocefin plate assay, as set forth above.

Step 4: Size Exclusion Chromatography for Obtaining Pure Monomer CAB1.11i

5 ml of concentrated CAB protein was loaded onto a Superdex 75 preparative grade column (Amersham Biosciences, product# 17-1070-01) equilibrated with PBS. Proteins were separated with a flow rate of 2 ml/min. of PBS and collected in 5 ml fractions.

Step 5: Removal of Endotoxin via Detoxi-Gel

1-4 ml of concentrated CAB protein was loaded onto a 10 ml Detoxi-Gel (immobilized polymixin-B, Pierce, product# 20339) column equilibrated with PBS. The sample was left bound to the resin for 2.5 hours before elating with PBS. Collect 20 1 ml fractions.

Assay individual fractions for β-lactamase using the nitrocefin plate assay and for endotoxin using the BioWhittaker QCL-1000 Chromogenic Endpoint LAL assay. Calculated endotoxin units per mg of CAB protein. The maximum limit for in vivo murine studies is 5 units/mg and, for PBMC immunogenicity assays, 0.2 units/mg.

FIG. 9 shows an SDS PAGE analysis of CAB1.11i protein of the protein that was purified by the above described procedure. Example 8 PBMC Assay of CAB1.11i

In order to test the potential immunogenicity of the CAB1.11i protein, the protein was tested in the PBMC proliferation assay. Community donor PBMC samples were purchased from the Stanford University Blood Center (Palo Alto, Calif.) or from BloodSource (Sacramento). Each sample was tested for common human bloodborne pathogens. PBMC were isolated from the buffy coat samples by differential centrifugation using Lymphocyte Separation Media (Gibco). PBMC were adjusted to 4×10̂6 per ml in 5% heat-inactivated human AB serum-containing RPMI 1640. Cultures were seeded at 2 ml per well in a 24 well plate (Costar). Purified proteins were added at 20 ug/ml final concentration, and the bulk cultures were incubated at 37° C., 5% CO₂ for 5 days. Five days was selected after testing cultures at 4, 5, 6 and 7 days. The optimum responses were seen at 5 days for most proteins, with the exception of robust secondary responses to proteins such as tetanus toxoid that often peaked at day 4. On day 5 the bulk cultures were resuspended and 100 ul aliquots of each culture were replicately plated into a 96 well plate. From 4 to 12 replicates were performed for each bulk culture. Tritiated thymidine was added at 0.25 uCi per well, and the replicates were cultured for 6 hours. Cultures were harvested to glass filtermats (Wallac) and the samples were counted in a scintillation counter (Wallac TriBeta). The CPM for each bulk culture were averaged. A control well with no added protein provided background CPM for each donor. A stimulation index for each test was calculated by dividing the experimental CPM by the control. An SI of 1.0 indicated that there was no proliferation above the background level. All purified protein samples were prepared in house. All proteins were tested for endotoxin using a commercially available kit (Pierce). All samples were adjusted to 1-2 mg/ml protein in PBS and were filter sterilized.

Thirty-six community donor samples were tested with the CAB1.11i protein. The average stimulation index was 1.06+/−0.25. This value is not different from background proliferation (SI=1.0). None of the thirty-six donors mounted a proliferative response greater than 1.99, the cut-off value for a positive response. This is in contrast to previously collected data for the unmodified beta-lactamase protein, which showed an average stimulation index of 2.35+/−3.50, and a 27% response rate in 26 community donor samples. The proliferation results for the CAB1.11i are lower than the stimulation index results for the beta-lactamase (p=0.03). No donors mounted a stimulation index of 1.99 or greater when tested with the CAB1.11i protein, as compared to the 27% responses to the beta-lactamase protein. Finally, the PBMC data for staphylokinase, a protein known to cause immune responses in community donors, was an average stimulation index was 3.68 +/−2.16, with a 70% response rate. The data for CAB1.11i is highly different from the staphylokinase data. These results are interpreted to suggest that the CAB1.11i protein is comparatively non-immunogenic when tested in this human cell based, in vitro proliferation assay.

Example 9 Binding of CAB1.11i to CEA

Purified CEA (Biodesign International) was immobilized onto 96 well Costar High binding plates by incubation with a 5 ug/ml solution in 50 mM NaHCO3 buffer at pH 9.6. A blocking step using casein to prevent non-specific binding was performed. Samples of purified CAB1.11i protein were pre-tested for their BLA enzymatic activity against nitrocefin substrate to determine the specific activity. CAB1.11i was diluted in 10 mM PBS buffer pH 7.1 to 30,000 units/ml concentration. A 2 fold serial dilution was prepared in the same buffer and 100 ul aliquots were added to the wells (8 samples: 3000, 1500, 750, 375, 187, 94, 47, 24 units). The protein was allowed to bind to the plates at ambient temperature for 1.5 h. The wells were extensively washed with PBS buffer containing Tween-20. The amount of CAB1.11i protein bound to the plates was determined my monitoring the amount of BLA remaining on the wells. The nitrocefin substrate (200 ul/well of 0.1 mg/ml solution) was added to the wells and the product of the reaction was recorded by measuring the Absorbance at 490 nm over a 20 min incubation period (ambient temperature). The V_(max) was determined for each protein concentration, and a binding curve was generated by plotted protein bound versus protein added, to determine the K_(d) apparent for the material.

Binding curves are plotted in FIG. 10A. CAB1.11i concentration was determined from measured BLA activity using a pre-determined conversion factor.

For apparent t_(1/2) determinations, the CAB1.11i protein bound following the above-described procedure was sequentially allowed to wash off by incubation of the wells in PBS-buffer pH 7.1 at ambient temperature. At prescribed times (0, 40, 80, 120 min) the buffer on the wells was removed and replaced with a nitrocefin substrate solution, and the BLA activity was determined as described above. The enzyme activity remaining bound (relative to time zero) was calculated, and the percent BLA activity bound (remaining) was plotted versus time to determine the 50% retention time.

The results can be seen in FIG. 10B.

Example 10 CAB1.11i Circular Dichroism

Circular-dichroism (CD) spectra were collected on an Aviv 215 spectrophotometer equipped with a 5-position thermoelectric cell holder supplied by Aviv. Buffer conditions were phosphate buffered saline at pH7.4 and protein concentration was 1 μM. Data was collected from 265 to 195 nm every 1 nm with a 1 nm bandwith in a 0.1 cm path length cell at 25° C. Data was collected for 5 seconds at each wavelength and three replicate spectra were averaged. The CD signal was converted to mean residue ellipticity (MRE). The CD Spectrum of CAB1.11i is indicative of a folded protein with both alpha helix and beta strand secondary structural components.

Example 11 Pharmacokinetics and Tissue Distribution of CAB1.11i in Xenograft Mouse Model of Human Colorectal Cancer

Ncr athymic nude mice), 18-22 g, approximately 6-8 weeks of age, were implanted subcutaneously with approximately 2 million tumor-derived LS174T human colorectal cancer cells. When tumors reached approximately >250 mm³, 12 animals were administered a single IV bolus injection of CAB1.11i (1 mg/kg) via the tail vein and 3 animals were untreated to provide control tissues. Three animals were anaesthetized and sacrificed at 0, 6, 12, 24 and 48 hr. Liver, kidney and tumor were harvested from each animal, snap frozen in liquid nitrogen and stored at approximately −70° C. until analysis. Blood was collected via cardiac puncture onto EDTA. Blood samples were centrifuged to separate plasma that was then stored at approximately −70° C. until analysis.

Tissue samples were homogenized on ice in PBS with 15 ug/mL aprotinin (2 mL buffer:gram tissue). Homogenate was mixed with B-PER (1:1) (from Pierce) and centrifuged. CAB1.11i concentrations in the tissue supernatant and plasma samples were determined by measuring BLA activity using a nitrocefin assay.

The results of this experiment indicated that CAB1.11i was rapidly eliminated from plasma, liver and kidney and localized to the TLS174T tumor (FIG. 12). High tumor to blood ratio of CAB1.11i concentrations were sustained and achieved (FIG. 13).

Example 12 Efficacy of CAB1.11i in a Xenograft Mouse Model of Human Colorectal Cancer

Ncr athymic nude mice, 18-22 g, approximately 6-8 weeks of age, were implanted subcutaneously with approximately 2 million tumor-derived LS174T human colorectal cancer cells (TLS174T). LS174T cells were obtained from ATCC, passaged through mice and re-isolated to generate TL174T. When tumors reach approximately >250 mm³, ten mice each were administered nothing or CAB1.11i (1 or 0.25 mg/kg followed by administration of, Glutaryl-C-Mel, GCR-2141, shown for example, in U.S. Pat. No. 5,773,435, as (150 mg/kg) 24 hours after CAB administration. All drugs were administered by IV bolus injections via the tail vein. Tumors were measured twice weekly.

The results of this study demonstrated that CAB1.11i at both 1 m/kg and 0.25 mg/kg doses in combination with the prodrug GCR-2141 at 150 mg/kg was active in a mouse model of human colorectal cancer (see FIG. 14).

Example 13 Construction of a Ropo2 Antibody

An antibody specific for BLA, Ropo2, was constructed as described. BLA was suspended in PBS Buffer (1 mg/ml), emulsified by mixing with an equal volume of Complete Freund's Adjuvant (Total volume of 0.6 ml) and injected into three to four subcutantous dorsal sites for primary immunization. Subsequent immunizations were performed using Incomplete Freund's Adjuvant at a dose of 200 ug/rabbit. For collection, animals were bled from the articular artery. The blood was allowed to clot and serum was collected by centrifugation. Serum was stored at −20C.

Example 14 Tumor Panel IHCs to Assess Distribution of Target Antigen and Binding Specificity

Frozen tissue samples used in this study were obtained from Ardais' BIGR® Library (Ardais). Genencor provided preparations of CABs as well as the rabbit polyclonal anti-BLA antibody, Ropo2. IHC analysis was used and as a positive control, a cytokeratin antibody (Dako Cytomation) was used. Please see Table 4.

TABLE 4 Antibody Source Concentration Species CAB 1.2i with 15-mer 1.4 mg/ml N/A CAB 1.11i 1.0 mg/ml N/A CAB 1.2i with 30-mer 3.0 mg/ml N/A CAB 1.14i 1.8 mg/ml N/A Ropo 2 αBLA 436 μg/ml Rabbit Cytokeratin Dako 0.2 mg/ml Mouse Cytomation

Frozen samples were removed at temperatures between −80° C. and placed in −20° C. for 2 hours. The cryostat was set at −20° C. and section samples were cut at 5 μm thickness. Sections were placed on Plus Slides and stored in a microscope slide box on dry ice while sectioning. Sections were air dried at room temperature for 30 minutes. Sections were placed in acetone at room temperature for 10 minutes. Sections were rinsed in Wash Buffer (Dako Cytomation, Code# S3006, Lot# 044312) 2-3×5 min at room temperature.

IHC was performed on a Dako autostainer. Antibodies were diluted in Antibody Diluent (Dalo Cytomation, Code# S0809, Lot# 123113) to the following concentrations: CAB antibodies to 0.2 μg/ml and Ropo 2 antibody to 0.1 μg/ml. Samples were incubated with approximately ˜200 μl Peroxidase Block for 5 minutes at room temperature. Antibodies were rinsed with wash buffer for 2×5 minutes. Samples were incubated with approximately ˜200 μl Protein Block (Dako Cytomation, Code #X0909, Lot# 103183) for 10 minutes. ˜200 μl CAB antibody was added for 30 minutes at room temperature. Samples were washed with Wash Buffer 2×5 minutes. Approximately ˜200 μl Ropo 2 antibody was added and incubation occurred for 30 minutes at room temperature. Samples were rinsed with Wash Buffer for 2×5 minutes. ˜200 μl Secondary Antibody from Detection System was added and incubated for 30 minutes. The samples were rinsed with wash buffer for 2×5 minutes. Samples were incubated in ˜200 μl Chromagen (DAB+ provided in Detection System (Envision+ System, HRP (DAB) Rabbit)—Dako Cytomation, Code# K4011, Lot# 11367)) for 5 minutes. The samples were washed with distilled water for 5 minutes. The samples were counterstained with Hematoxylin (Richard Allen, Code# 7211, Lot# 35053), which provides a blue nuclear stain, for 30 seconds. The samples were rinsed for 5 minutes. Samples were dipped twice in a Bluing Reagent (Richard Allen, Code# 7301, Lot# 19540). Samples were rinsed with distilled water for 5 minutes. Samples were dehydrated in 95% Ethanol 2×2 minutes, 100% Ethanol 2×2 minutes and cleared in Xylene. Samples were mounted with Medium (Richard Allen, Code# 4111, Lot# 18071), and a coverslips were added.

In this IHC study, the four CAB antibodies CAB 1.2i, 15-mer linker, CAB 1.2i, 30-mer linker, CAB 1.11i and Cab 1.14i were analyzed against a tissue panel consisting of 5 lung, 3 colon, and 5 pancreatic tumor samples.

FIG. 15 shows the full results of the study. The first column details the case diagnosis; the second column details the tissue of origin and site of finding; the fourth column shows staining with the anti-human cytokeratin AE1/AE3, columns five through eight show staining against the four antibodies, CAB 1.2i with a 15-mer linker, CAB 1.2i with a 30-mer linker, CAB1.11i and CAB1.14i.

The four antibodies showed robust immuno staining (intensity of 2−3+) in all of the tumor samples tested and were very similar if not identical in their staining patterns. All samples with the exception of one, CI000005496-FF5, demonstrated staining in greater than 75% of tumor cells present. Minimal, pale (1−2+) staining, which is sometimes seen with frozen tissue sections, was also observed in stromal cells, including fibroblasts and occasional mixed inflammatory cells. Necrotic cells and intra-alveolar macrophages (seen in samples of lung tissue) consistently showed positive staining.

Adjacent normal tissue present in the samples was largely negative, with no positive staining seen in normal lung or pancreatic tissue. Normal liver tissue seen in sample CI0000008475, a case of colon cancer metastatic to the liver, showed pale staining that was limited to the sinusoidal regions with 3 of the antibodies (CAB 1.2i 15-mer linker, CAB 1.11i, and CAB 1.2i, 30-mer linker). The fourth antibody (CAB 1.14i) showed stronger, more diffuse staining of 90% of normal liver parenchyma.

In comparing the staining characteristics of the four antibodies tested, there was only minimal variability observed. Of the four antibodies tested, CAB 1.14i appeared to show slightly more background staining.

The cytokeratin antibody, which was used on selected samples to ensure that the tissue antigens were properly preserved, showed strong positive staining of epithelial cells. There was no staining seen in the ‘no-primary antibody’ controls.

Example 15 Pharmacokinetics and Tissue Distribution of GC-Mel Administered at Various Intervals Following CAB 1.11i in LS174T Xenograft Bearing Nude Mice

We assessed the tumor retention characteristics of CAB1.11i by monitoring the formation of Mel from the administration of GC-Mel. Dosing solutions were prepared on the day of dosing, within 60 minutes of administration.

The concentration of the formulation of GC-Mel in bicarbonate/sucrose was based on average rat weight, the desired volume of administration and a dose level of 150 mg/kg. GC-Mel was weighed out and, based on this weight, the appropriate amount of sodium bicarbonate to neutralize all 3 equivalents of the three carboxylic acid sites of GC-Mel was determined. Vehicle was prepared in the required volume by adding the precalculated sodium bicarbonate solution in 5% aqueous sucrose. Vehicle was prechilled at 4° C. Cold vehicle was added to the GC-Mel powder and the mixture was vortexed and sonicated to achieve speedy dissolution.

Female Ncr athymic nude mice (n=250), having a body weight of 18-22 g and being approximately 6-8 weeks of age, were obtained from Taconic (Germantown, N.Y.).

The animals were be implanted subcutaneously on the flank with 2×10⁶ TLS174T cells, a human colorectal tumor line, in 100 μl of phosphate buffered saline. Beginning approximately one week after tumor cell implant, tumors were measured every 3 to 4 days. When the tumors reached approximately 100-250 mm³, 156 animals were selected based on tumor size and randomized into 7 groups, resulting in a non-significant difference in the mean tumor size between groups at the start of the experiment.

Mice were warmed with a heating lamp and heating pad, placed in a restrainer and the test compounds were administered by bolus intravenous injection via the tail vein. For the blood sampling, all mice were anesthetized by isoflurane inhalation at the time of sample collection. Blood was collected by cardiac puncture into tubes containing EDTA and placed on ice. Tubes were centrifuged at 4000 RPM for two minutes. The plasma fraction was removed into a pre-labeled microfuge tube and placed on dry ice or liquid nitrogen. Sample concentrations were determined.

Tissue samples were rinsed 1× in phosphate buffered saline to remove blood. The samples were snap frozen using liquid nitrogen or dry ice. Tissue samples were stored at −70° C. prior to analysis.

TLS174T is a cell line established from LS174T by passaging the parental cell line in-vivo. TLS174T cell line was originally purchased from ATCC (Manassas, Va.). TLS174T cells routinely test negative for mycoplasma contamination (MycoAlert Mycoplasma Detection Kit, Cambrex). TLS174T cells were used for the in-vivo studies between passage 3 and 15 and were in log phase growth at the time of harvest for implanting. The cells were maintained in 87% Dulbecco's Modified Eagle's Medium (Cellgro (Herndon, Va.))/Hams F12 (Cellgro (Herndon, Va.)) (1:1) containing 10% fetal calf serum (HyClone (Salt Lake City, Utah)), 1% sodium pyruvate (final concentration=1 mM) (Cellgro (Herndon, Va.)), 1% non-essential amino acids (Cellgro (Herndon, Va.)), 1% L-glutamine (final concentration=2 mM) (Cellgro (Herndon, Va.)). The passage number of the cells used for this study was 5. The level of CEA expression was checked by FACS analysis.

For implantation, TLS174T were plated at 4-5E4 cells/cm² (2-2.5E7 cells/500 cm² (Nunc Triple Flask or 0.9-1.1E7 cells/225 cm²). This is equivalent to a 1/12 split. Cells were expected to reach approximately 85-90% confluency in 72 hrs with approximate cell recovery of 1.3-1.5E8 cells per TF or 5.9-6.8E7 cells per T-225.

The study design is outlined in Table 5. Animals in Group 1 (n=3) served as the non-treated control group. Animals in Group 2 (n=42) were dosed intravenously with CAB 1.11i (1 mg/kg). Animals in group 3 (n=3) were dosed intravenously with Mel (150 mg/kg). Animals in group 4 (n=27) were dosed intravenously with CAB 1.11i (1 mg/kg). After 24 hr, the animals were dosed intravenously with 150 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Group 5 (n=27) were dosed intravenously with CAB 1.11i (1 mg/kg). After 48 hr, the animals were dosed intravenously with 150 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Group 6 (n=27) were dosed intravenously with CAB 1.11i (1 mg/kg). After 72 hr, the animals were dosed intravenously with 150 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Group 7 (n=27) were dosed intravenously with CAB 1.11i (1 mg/kg). After 96 hr, the animals were dosed intravenously with 150 mg/kg GC-Mel in sucrose/NaHCO₃ buffer.

TABLE 5 Time of CAB 1.11i GC-Mel GC-Mel Group N/sex (1 mg/kg) (150 mg/kg) admin. 1  3/F − − − 2 42/F + − − 3  3/F − + − 4 27/F + + 24 5 27/F + + 48 6 27/F + + 72 7 27/F + + 96 ¹Time of administration, post CAB 1.11i administration ²Collected post GC-Mel administration

Blood samples for plasma were taken from the animals in Group 1 at time 0. Blood samples were taken from the animals in Group 2 at 0.033, 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72 and 96 hr after CAB 1.11i injection. Blood samples for plasma were taken from the animals in Group 3 at 0.033 hr. Blood samples for plasma were taken from the animals in Groups 4-7; 0.033, 0.083, 0.25, 0.5, 1, 2, 3, 4 and 6 hr after GC-Mel injection.

Tissue (tumor, kidney, liver) samples were taken from the animals in group 1 at zero time. Tissue (tumor, kidney, liver) samples were taken from the animals in group 2 at is 0.033, 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72 and 96 hr after CAB 1.11i injection. No tissue samples were collected from group 3. Tissue (tumor, kidney) samples were taken from the animals in groups 4-7 at 0.033, 0.083, 0.25, 0.5, 1, 2, 3, 4 and 6 hr. The samples were snap frozen using liquid nitrogen or dry ice and methanol. The tissue samples were stored at −70° C. prior to analysis.

The results are shown in FIGS. 16-18. As can be seen from the results, plasma Mel decreased to near background (concomitant) levels at 96 hrs. Also, efficacy demonstrated with 24 hour intervals suggest similar anti-tumor activity likely at later intervals for GC-Mel with reduced plasma concentration. It is important that exposure to Mel is increased at the tumor site and decreased at locations not affected by tumor (to minimize potential side affects). This may require that CAB 1.11i be given sufficient time in advance of the prodrug so that CAB can localize to the tumor and unbound CAB can clear. From our data, it appears that some interval, such as 24 hours, is essential. Accordingly, dosing interval may be very important, even critical.

Example 16 Antitumor Activity of CAB 1.2i, 15-mer, CAB 1.2i 30-mer CAB 1.14i and Cab 1.11i Followed by Administration of GC-Mel in the Tumor-Derived TLS174T Tumor Bearing Female Athymic Mice

Dosing solutions were prepared on the day of dosing, within 60 minutes of administration. An aliquot of each formulated dosing solution was retained and stored at −70° C. prior to analysis. CABs were analyzed for protein concentration and BLA activity. GC-Mel and Mel were analyzed for compound concentration.

Bulk GC-Mel was weighed and dissolved in 3.0 eq of 1.0 M NaHCO₃. Solutions were mixed well by vortex and diluted with 5% aqueous sucrose solution to 30 mg/mL final concentration, as above. Animals received 100 μL formulated dosing solution.

Bulk Mel was weighed and dissolved in 20% DMSO in acidified PBS (pH 4.0) to 2 mg/mL final concentration. Animals received 100 μL each formulated dosing solution.

One hundred and fifty female Ncr athymic mice, 18-22 g, approximately 6-8 weeks, from Taconic Labs were implanted with TLS174T human colorectal tumors. One hundred animals were selected for dose administration based on tumor size and growth rate.

Study design is outlined in Table 6. Mice were implanted with TLS174T cells (Study Day 0) and when tumors reached approximately ≧250 mm³, 100 animals were selected based on tumor size and growth rate and sorted into 10 groups resulting in similar mean tumor size between groups. Ten mice each were administered CAB 1.2i, 15-mer, CAB 1.14i or CAB 1.11i (1 or 0.25 mg/kg) or CAB 1.2i, 30-mer (0.25 mg/ml) followed by GC-Mel (150 mg/kg) 24 hours after CAB administration. Ten mice each were administered vehicle, Mel (10 mg/kg) or GC-Mel (150 mg/kg).

TABLE 6 GC-Mel Dose Dose² Group N/Sex Test Article (mg/kg) (mg/kg) Observations 1 10/F Vehicle¹ — — Body weight: 2 10/F Mel 10 — weekly 3 10/F CAB 1.2i 0.25 150 Cage side 4 10/F — — 150 observations: 5 10/F CAB 1.2i, 15- 0.25 150 daily mer Tumor 6 10/F CAB 1.2i, 15- 1 150 Measurements: mer twice weekly 7 10/F CAB 1.11i 0.25 150 8 10/F CAB 1.11i 1 150 9 10/F CAB 1.14i 0.25 150 10 10/F CAB 1.14i 1 150 ¹Five animals will be administered 1:10 dilutions in PBS of 20 mM sodium citrate, 150 mM NaCl, pH 6.0 and five animals will be administered 20% DMSO in acidified PBS (pH 4.O) ²GC-Mel administered 24 hours post-CAB administration.

One hundred and fifty female mice were implanted with TLS174T cells by subcutaneous injection suspended in DMEM at 2×10⁷ cells/mL. Animals were anesthetized by isofluorane inhalation, and cells were implanted by subcutaneous injection of 100 μL cell suspension (approximately 2×10⁶ cells/mouse). The day of implantation was designated as Study Day 0.

After tumor implantation, animals were observed daily at minimum and moribund or distressed animals were euthanized. Tumors were measured twice weekly, and body weights were recorded weekly.

When tumors reached ≧250 mm³, animals were assigned to) groups. Mice were weighed on the day of dosing, and doses were based on the average weight of all animals. Mice were warmed with a heating lamp and heating pad and placed in a restrainer. The tail was wiped with 70% alcohol and doses were administered by bolus intravenous injection via the tail vein.

Treatment groups whose average tumor volume exceeded 1500 mm³ were euthanized, and individual animals whose tumor was excessively large and/or necrotic were euthanized. A treatment group was euthanized if fewer than 6 animals remain in the study, except to monitor individual animals that achieved a complete response for tumor regrowth.

On Day 45, remaining mice were euthanized by CO₂ inhalation and underwent necropsy. Abnormal tissues or organs were formalin fixed for histopathology. Tumors were collected from all animals into formalin for histopathology.

Results can be seen in FIG. 19. The CABs, followed by administration of prodrug, showed a decrease in tumor volume. However, the same group, showed some weight loss.

Example 17 Immunogenicity of wt BLA, GCR-8886 and CAB1.2i After IV or IP Administration to Normal Mice

CAB1.11i and CAB1.2i were diluted in PBS to 200 ug/ml. For the i.p. group (group 5), CAB1.11i was diluted in a 1:1 solution of alum to PBS (resulting concentration=200 ug/ml) and vortexed rapidly for 10 minutes. The mixture was left at 2-8° C. for a minimum of 15 minutes. The mixture was revortexed 1 minute prior to injection into mice. The dosing solution was stored on ice prior to administration.

Wt BLA was diluted in PBS to 400 ug/ml. For the i.p. group, group 4, wt 13LA was diluted in a 1:1 solution of alum to a PBS with resulting concentration=200 ug/ml and vortexed rapidly for 10 minutes. The mixture was left at 2-8° C. for a minimum of 15 minutes. The mixture was then revortexed 1 minute prior to injection into mice. The solution was stored on ice prior to administration.

Study design is outlined in Table 7. Female CB6F1/J mice were used for each group. Mice undergoing i.v. injections were placed under a heating lamp for approximately 3 minutes to vasodilate the tail vein, and then placed in a mouse restrainer for the i.v. injection. On days 1, 8 and 15, three mice of each strain each were administered CAB1.2i (20 ug), CAB1.11i (20 ug), or wt BLA (20 ug) intravenously, or wt BLA (20 ug) or CAB1.11i (20 ug) complexed with alum administered by an i.p. injection. Dose concentrations and volumes are outlined in Table 8. Dose concentrations were formulated based on a 100 uL injection/mouse.

TABLE 7 Study Design Number Dose # of Days of Group Animals Test Article ROA (ug) Doses administration 1 3 wt BLA iv 20 3 1, 8 and 15 2 3 CAB1.11i iv 20 3 3 CAB1.2i iv 20 4 3 wt BLA in ip 20 alum 5 3 CAB1.11i ip 20 in Alum

TABLE 8 Dose Concentrations Dose Concentration Group Test Article (ug) (ug/mL) 1 wt BLA 20 200 2 CAB1.11i 20 200 3 CAB1.2i 20 200 4 wt BLA in alum 20 200 5 CAB1.11i in alum 20 200

After CAB1.2i or CAB1.11i injection, animals were observed twice weekly and moribund or distressed animals were euthanized. On Days 8, 13 and 20, mice were anesthetized using isofluorane and blood was collected into microtainer serum tubes by tail bleed. On Day 20, mice were euthanized for collection of spleens and lymph nodes.

Cells were recovered for T-cell proliferation assays (see, for example, U.S. Pat. No. 6,835,550, which is incorporated by reference, herein, including any drawings). Results are shown in FIG. 20, where the x-axis shows the type of conjugate administered, and the y-axis shows the anti-test article measured in IgG1 antibodies ng/ml. As can be seen from the Figure, wt BLA administered IP showed the greatest antibody response.

Example 18 Dose-Ranging Efficacy Study in LS174t Xenograft Bearing NCR Nude Mice

Materials were prepared as above.

Female Ncr athymic nude mice (n=100) having a body weight of 18-22 g and being approximately 6-8 weeks of age, were obtained from Taconic (Germantown, N.Y.). The animals (n=100) were implanted, study day 0, subcutaneously on the flank with 5×10⁶ LS174T cells in 100 μl of phosphate buffered saline. Beginning approximately one week after tumor cell implant, the tumors were measured every 3 to 4 days. When the tumors reached approximately 100-250 mm³, 93 animals were selected based on tumor size and randomized into 9 groups, resulting in a non-significant difference in the mean tumor size between groups at the start of the experiment.

Mice were warmed with a heating lamp and heating pad, placed in a restrainer and the test compounds were administered by bolus intravenous injection via the tail vein. For blood sampling, all mice were anesthetized by isoflurane inhalation at the time of sample collection. Blood was collected by cardiac puncture into tubes containing EDTA and placed on ice. Tubes were centrifuged at 4000 RPM for two minutes. The plasma fraction was removed into a pre-labeled microfuge tube and placed on dry ice or liquid nitrogen. All plasma samples were stored at −70° C. prior to analysis.

LS174T cells were originally purchased from ATCC (Manassas, Va.). The cells were routinely tested negative for mycoplasma contamination (MycoAlert Mycoplasma Detection Kit, Cambrex). LS174T cells were used for the in vivo studies between passage 2 and 15 and were in log phase growth at the time of harvest for implanting. Cells were maintained in 87% Dulbecco's Modified Eagle's Medium (Cellgro (Herndon, Va.))/Hams F12 (Cellgro (Herndon, Va.)) (1:1) containing 10% fetal calf serum (HyClone (Salt Lake City, Utah)), 1% sodium pyruvate (final concentration=1 mM) (Cellgro (Herndon, Va.)), 1% non-essential amino acids (Cellgro (Herndon, Va.)), 1% L-glutamine (final concentration=2 mM) (Cellgro (Herndon, Va.)). Passage number of the cells used for this study was 2. CEA expression was checked by FACS analysis.

Study design is outlined in Table 9. The animals in Group 3 (n=10) served as the non-treated control group. The animals in Group 1 and 2 (n=3) were dosed intravenously with CAB1.11i (1 mg/kg). After 72 and 96 hours, the animals were dosed intravenously with 50 mg/kg GC-Mel in sucrose/NaHCO₃ buffer respectively. The animals in Group 3 (n=10) served as the non-treated control group. The animals in Group 4 (n=10) were dosed intravenously with CAB1.11i (1 mg/kg). After 72 hr, the animals were dosed intravenously with vehicle of GC-Mel-sucrose/NaHCO₃ buffer. The animals in Group 5 (n=10) were dosed intravenously with CAB1.11i (1 mg/kg). After 72 hr, the animals were dosed intravenously with 150 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Group 6 (n=10) were dosed intravenously with CAB1.11i (1 mg/kg). After 72 hours, the animals were dosed intravenously with 300 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Group 7 (n=10) were dosed intravenously with CAB1.11i (1 mg/kg). After 72 hr, the animals were dosed intravenously with 600 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Group 8 (n=10) were dosed intravenously with CAB1.11i (1 mg/kg). After 72 hr, the animals were dosed intravenously with 900 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Group 9 (n=10) were dosed intravenously with CAB1.11i (1 mg/kg). After 96 hr, the animals were dosed intravenously with 900 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Group 10 (n=10) were dosed intravenously with CAB1.11i (5 mg/kg). After 96 hr, the animals were dosed intravenously with 900 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Group 11 (n=10) were dosed intravenously with CAB1.11i (5 mg/kg).

TABLE 9 Time of GC-Mel PK plasma Tumor N/sex administration sampling for sampling for Tumor CAB1.11i GC-Mel (Post GC-Mel, Mel: GC-Mel, Mel: Group (Size, mm³) (mg/kg) (mg/kg) CAB 1.11i) (Hr) (Hr) 1  3/F 1  50 72 0.25 0.25 (55-130) 2  3/F 1  50 96 0.25 0.25 (55-130) 3 10/F none none none N/A N/A (55-130) 4 10/F 1  0 72 N/A N/A (55-130) vehicle 5 10/F 1 150 72 N/A N/A (55-130) 6 10/F 1 300 72 N/A N/A (55-130) 7 10/F 1 600 72 N/A N/A (55-130) 8 10/F 1 900 72 N/A N/A (55-130) 9 10/F 1 900 96 N/A N/A (55-130) 10 10/F 5 900 96 N/A N/A (55-130) 11 10/F 5  0 96 N/A N/A (55-130)

Blood and tissue samples were taken from the animals in Groups 1 and 2 at time 0.25 hours after GC-Mel injection for pharmacokinetic analysis done by LC/MS/MS. Tumor and body weight of the animals were measured periodically.

Results are shown in FIG. 21. The Figure shows cytotoxic activity of CAB1.11i/GC-Mel. The x-axis shows days, and the y-axis shows the average tumor volume as measured in mm.³ From the Figure, one can see tumor volume shrank in all lines, except those of the control and species treated with CAB1.11i, alone.

Example 19 Dose-Ranging Toxicity Profile of GC-Mel Administered 72OR 96 Hours After CAB1.11i in NCR Nude Mice Bearing TLS174T Xenograft Tumors

Materials were prepared as above.

The concentration of the GC-Mel formulation in bicarbonate/sucrose was based on average rat weight, the desired volume of administration and the dose level of 150 mg/kg. GC-Mel was weighed out. Based on GC-Mel weight, the appropriate amount of sodium bicarbonate is to neutralize all 3 equivalents of the three carboxylic acid sites of GC-Mel was determined. Vehicle was prepared in the required volume by adding the precalculated sodium bicarbonate solution in 5% aqueous sucrose. 5% sucrose was used since bicarbonate serves as neutralizing agent and does not persist in the above formulation of GC-Mel. Vehicle was prechilled at 4° C. Cold vehicle was added to the GC-Mel powder and the mixture and vortexed and sonicated, if needed, to achieve speedy dissolution.

Female Ncr athymic nude mice (n=250), having a body weight of 18-22 g and being approximately 6-8 weeks of age, were obtained from Taconic (Germantown, N.Y.). Animals (n=150) were implanted on study day 0, subcutaneously on the flank with 10×10⁶ TLS174T cells in 100 μl of phosphate buffered saline. Approximately one week after tumor cell implant, tumors were measured every 3 to 4 days. When the tumors reached approximately 100-250 mm³, 108 animals were selected based on tumor size and randomized into 22 groups, resulting in a non-significant difference in the mean tumor size between groups at the start of the experiment.

Mice were warmed with a heating lamp and heating pad, placed in a restrainer and test compounds were administered by bolus intravenous injection via tail vein. For the blood sampling, all mice were anesthetized by isoflurane inhalation at the time of sample collection. Blood was collected by cardiac puncture into tubes containing EDTA and placed on ice. Tubes were centrifuged at 4000 RPM for two minutes. Plasma fraction was removed into a pre-labeled microfuge tube and placed on dry ice or liquid nitrogen. All plasma samples were stored at −70° C. prior to analysis.

For implantation, TLS174T were plated at 4-5E4 cells/cm² (2-2.5E7 cells/500 cm² (Nunc Triple Flask or 0.9-1.1E7 cells/225 cm²). This is equivalent to a 1/12 split. Cells reach approximately 85-90% confluency in 72 hrs with approximate cell recovery of 1.3-1.5E8 cells per TF or 5.9-6.8E7 cells per T-225.

Study design is outlined in Table 10. The animals in Group 1 (n=5) served as the non-treated control group. The animals in Group 2 (n=5) were dosed intravenously with PBS—CAB1.11i vehicle followed with sucrose/NaHCO₃ buffer—GC-Mel vehicle. The animals in Group 3 (n=5) were dosed intravenously with Cab1.11i (1 mg/kg). The animals in Groups 4 (n=3), 7 and 13 (n=5) were dosed intravenously with CAB1.11i (1 mg/kg). After 72 hr (Groups 4 and 7) and after 96 hr (Group 13), the animals were dosed intravenously with 150 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Group 5 (n=5) were dosed intravenously with CAB1.11i (1 mg/kg). After 72 hr the animals were dosed intravenously with GC-Mel vehicle sucrose/NaHCO₃ buffer. The animals in Groups 6 and 12 (n=5) were dosed intravenously with CAB1.11i (1 mg/kg). After 72 hr (Group 6) and after 96 hr (Group 12), the animals were dosed intravenously with 75 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Groups 8 and 14 (n=5) were dosed intravenously with CAB1.11i (1 mg/kg). After 72 hr (Group 8), and after 96 hr (Group 14), the animals were dosed intravenously with 300 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Groups 9 and 15 (n=5) were dosed intravenously with CAB1.11i (1 mg/kg). After 72 hr (Groups 9) and after 96 hr (Groups 15), the animals were dosed intravenously with 450 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Groups 10 and 16 (n=5) were dosed intravenously with CAB1.11i (1 mg/kg). After 72 hr (Group 10) and after 96 hr (Group 16), the animals were dosed intravenously with 600 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Groups 11 and 17, (n=5) were dosed intravenously with CAB1.11i (1 mg/kg). After 72 hr (Group 11) and after 96 hr (Group 17), the animals were dosed intravenously with 750 mg/kg GC-Mel in sucrose/NaHCO₃ buffer. The animals in Groups 18, 19, 20 and 21 (n=5) were dosed only with GC-Mel at 300 mg/mL, 450 mg/mL, 600 mg/mL and 750 mg/mL, respectively.

TABLE 11 Time of GC-Mel PK Sampling: Tissue administration GC-Mel/Mel Sampling: CAB1.11i GC-Mel (Post GCR- (plasma) (tumor) Body Group N/sex (mg/kg) (mg/kg) 8886) (Hr) (Hr) (Hr) weights 1 5/F none none N/A N/A N/A 2x weekly 2 5/F Vehicle Vehicle N/A N/A N/A 2x weekly 3 5/F 1  0 N/A N/A 2 N/A 4 3/F 1 150 72 0.033 N/A N/A 5 5/F 1  0 72 N/A N/A 2x weekly vehicle 6 5/F 1  75 72 N/A N/A 2x weekly 7 5/F 1 150 72 N/A N/A 2x weekly 8 5/F 1 300 72 N/A N/A 2x weekly 9 5/F 1 450 72 N/A N/A 2x weekly 10 5/F 1 600 72 N/A N/A 2x weekly 11 5/F 1 750 72 N/A N/A 2x weekly 12 5F 1  75 96 N/A N/A 2x weekly 13 5/F 1 150 96 N/A N/A 2x weekly 14 5/F 1 300 96 N/A N/A 2x weekly 15 5/F 1 450 96 N/A N/A 2x weekly 16 5/F 1 600 96 N/A N/A 2x weekly 17 5/F 1 750 96 N/A N/A 2x weekly 18 5/F 0 300 N/A N/A N/A 2x weekly 19 5/F 0 450 N/A N/A N/A 2x weekly 20 5/F 0 600 N/A N/A N/A 2x weekly 21 5/F 0 750 N/A N/A N/A 2x weekly

The results can be seen in FIG. 22 Average body weight loss was less than 20% for all dose groups, indicating that dose limiting toxicity was not achieved using these dose regimens. Example 20 Pharmacokinetics of CAB1.11i Following Intravenous Bolus Administration to Sprague-Dawley Rats

Materials were formulated as described above.

Male and female Sprague-Dawley rats were assigned to the study based on catheter patency and acceptable health as determined by an attending veterinarian. Animals were placed into three groups of four animals per sex per group. For Group 1, each animal received CAB1.11i (0.25 mg/mL) as an intravenous bolus injection into the femoral vein cannula at a target dose level of 0.25 mg/kg, and at a dose volume of 1 mL/kg. For Group 2, each animal received CAB1.11i (0.25 mg/mL) as an intravenous bolus injection into the femoral vein cannula at a target dose level of 1 mg/kg, and at a dose volume of 4 mL/kg. For Group 3, each animal received CAB1.11i (1.36 mg/mL) as an intravenous bolus injection into the femoral vein cannula at a target dose level of 5 mg/kg and at a dose volume of 3.68 mL/kg.

Following each dose, the femoral vein catheter was flushed with 0.5 mL of saline and tied-off to prevent re-access. All doses were administered without incident except for animal number 16 (Group 2), number 20 (Group 3) and number 24 (Group 3). Due to insufficient dose solution, animal numbers 16 and 20 were not dosed and animal number 24 did not receive its full dose volume.

Throughout dosing and sample collection, the animals were observed for any clinically relevant abnormalities, and the following were noted (Table 10):

TABLE 10 Group Animal Time No. No. Post-Dose Clinical Observation 2 11 2 minutes Animal exhibited mild soft feces.

Blood samples (0.25 mL; EDTA anticoagulant) were collected via the jugular vein cannula prior to each dose and at 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 8, 12, 24, 48, 72 and 96 hours following intravenous administration. Blood samples were placed on ice and were centrifuged at 1000×g (5° C.) to harvest plasma within 15 minutes of blood collection.

The results can be seen in FIG. 23. This study was compromised by dimer, but does indicate that PK is dose proportional in the animal model. FIG. 24 shows that dimer content effects disposition-low dimer (squares) CAB1.11i is eliminated more rapidly than high dimmer (circles).

Example 21 Pharmacokinetics of CAB1.11i Following Intravenous Bolus Administration of Sprague-Dawley Rats

0.0049 g Mel was prepared as set forth above. Mel was combined with 4.91 mL (4.87 g) of DMSO vehicle (20% DMSO, 80% aqueous containing 0.15 M NaCl and 5×10⁻⁴ M HCl). The formulation was mixed by inversion and vortexed for a total of 8 minutes to produce a clear colorless solution with a target concentration of 1 mg/mL for intravenous administration. No dosing was required for Group 1.

Nineteen male Sprague-Dawley rats were assigned to the study based on catheter patency and acceptable health as determined by an attending veterinarian. The animals were placed into five groups of three animals per group and one group of four animals. The animals in Group 1 received no dose administration and were used to provide blank plasma and urine to be used for sample analysis. The animals in Group 2 received Mel as an intravenous bolus injection into the femoral vein catheter at a target dose level of 2 mg/kg and at a dose volume of 2 mL/kg. The animals in Group 3 received a TAG-72 binding construct as an intravenous bolus injection into the femoral vein catheter at a target dose level of 1 mg/kg and at a dose volume of 1 mL/kg. The animals in Group 4 received a Muc-1 binding construct as an intravenous bolus injection into the femoral vein catheter at a target dose level of 1 mg/kg and at a dose volume of 1 mL/kg. The animals in Group 5 received CAB1.11i as an intravenous bolus injection into the femoral vein catheter at a target dose level of 1 mg/kg and at a dose volume of 1.02 mL/kg. The animals in Group 6 received a similar CAB1.11i as an intravenous bolus injection into the femoral vein catheter at a target dose level of 1 mg/kg and at a dose volume of 1 mL/kg.

Following dosing, the femoral dosing catheter was flushed with 0.5 mL of saline and tied-off to prevent re-access. Throughout dosing and sample collection, the animals were observed for any clinically relevant abnormalities, and the following were noted

TABLE 12 Animal Time Group No. Post-Dose Clinical Observation 3 8 30 min Animal exhibited mild soft feces.

Following dosing, each animal was transferred to a separate Nalge rodent metabolism cage for collection of voided urine. Urine was collected on cold packs from each animal in Group 1 for 48 hours. Voided urine was collected on dry ice from each animal in Groups 2-6 at 0-24 and 24-48 hours following dose administration. The urine collected from the Group 1 animals was pooled, then divided into two approximately equal aliquots.

Blood samples were collected from each animal via the jugular vein catheter into tubes containing EDTA anticoagulant. For Group 1, the maximum obtainable volume was collected from each animal following the 48-hour urine collection. For Groups 2-6, blood samples (0.3 mL each, but the maximum obtainable volume at last the timepoint) were collected via the jugular vein catheter prior to each dose and at 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 8, 12, 24, and 48 hours following intravenous administration. Additional blood samples were collected from the animals in Groups 3-6 at 72 and 96 hours post-dose. Due to a technician error, a terminal blood sample was collected from animal number 8 (Group 3) at 48 hours post-dose. As a result, the 72 and 96-hour post-dose blood samples were not collected from this animal. Blood samples were placed on ice until centrifuged at about 5° C. to isolate plasma within 30 minutes after blood collection. Each plasma sample from the Group 1 animals was divided into two approximately equal aliquots. A single plasma aliquot was prepared from each blood sample collected from the animals in Groups 2-6.

Following terminal blood collection and euthanasia, the bone marrow (both femurs), kidneys and liver were collected from the Group 2 animals only. The weights of the tissues were not recorded.

The results are shown in FIG. 24.

Example 22 The Effect of CEA Administration on the Pharmacokinetics of CAB1.11i Following Intravenous Administration to Cynomolgus Monkeys

Materials were prepared as set forth above.

Aliquots of the CAB1.11i formulations for Groups 1-3 were diluted in PBS and the absorbance of each diluted sample was determined in triplicate at 280 nm using a spectrophotometer. For Group 5, CEA stock solution (0.862 mg/mL, 325 uL) was combined with PBS (325 uL) to produce a total volume of 650 uL at a concentration of 0.431 mg/mL. The diluted CEA (0.508 mL, 0.431 mg/mL) was added to a tube containing 8.75 mL of CAB1.11i at 1 mg/mL concentration. The CEA was added to CAB1.11i 30 minutes prior to dosing and kept at room temperature. For Group 6, 2.54 mL of stock CEA (0.862 mg/mL) was added to a tube containing 8.75 mL of CAB1.11i at 1 mg/mL concentration. The CEA was added to CAB1.11i 30 minutes prior to scheduled dosing and kept at room temperature. For the Day 8 dosing of the Group 3 animals, additional pre-formulated 5 mg/mL CAB1.11i was used. A dose formulation sample (0.1 mL each) was collected from this dose solution. The dose formulation sample and residual dose formulation were stored at 5±3° C.

Six male and four female cynomolgus monkeys were selected and placed into six groups of two animals per group. One male and one female were assigned to Groups 1, 2, 4 and 6, and two males were assigned to Group 5. One treatment naïve male and one treatment naïve female cynomolgus monkey were assigned to Group 3. All animals were equipped with a chronic venous catheter and subcutaneous vascular access port (VAP) to facilitate blood collection. The animals were assigned to the study based on acceptable health as determined by a staff veterinarian following a pre-study health evaluation. The pre-study health evaluation included serum chemistry and hematology evaluations as well as a physical exam. Animals had previously been acclimated to primate chairs and rope/pole and collar restraint. Animals were restrained in primate chairs for dosing and for up to the first two hours of blood collection before being returned to their individual cages. Fasting of the animals before or after dosing was not required.

Prior to dosing, a temporary percutaneous catheter was placed in a saphenous or cephalic vein of each animal. All doses were administered via a percutaneous venous catheter. The animals in Group 1 received a bolus administration of prepared CAB1.11i at a target dose level of 0.25 mg/kg and at a dose volume of 1 mL/kg. The animals in Group 2 received a bolus administration of prepared CAB1.11i at a target dose level of 1 mg/kg and at a dose volume of 1 mL/kg. On Day 1 and Day 8, the animals in Group 3 received a bolus administration of prepared CAB1.11i at a target dose level of 5 mg/kg and at a dose volume of 1 mL/kg. The animals in Group 4 received a bolus administration of prepared CEA at a target dose level of 0.25 mg/kg and at a dose volume of 0.290 mL/kg. The animals in Group 5 received a bolus administration of the prepared CAB1.11i/CEA mixture at target dose levels of 1 mg/kg CAB1.11i and 0.025 mg/kg CEA and at a dose volume of 1.058 mL/kg. The animals in Group 6 received a bolus administration of the prepared CAB1.11i/CEA mixture at target dose levels of 1 mg/kg CAB1.11i and 0.25 mg/kg CEA and at a dose volume of 1.290 mL/kg.

Immediately following each intravenous dose, the dosing catheter was flushed with approximately 3 mL saline prior to removal. Each dosing syringe was weighed before and after dosing to gravimetrically determine the quantity of formulation administered. Dose administration data including pre-dose animal body weights are presented in Table 13.

TABLE 13 Treatment Number of Dose Dose Dose Total Dose Dose Group Animals Test Level Conc. Volume combined Re- Number Male Female Article (mg/kg) (mg/mL) (mL/kg) (mL/kg) gimen Dose Vehicle Dose Route Flush 1 1 1 CAB1.11i 0.25 0.25 1 1 Day 1 PBS + 25 mM Intravenous 3 mL Phosphate (Na & bolus saline 2 1 1 CAB1.11i 1 1 1 1 Day 1 K)/145 mM NaCl, 5% Intravenous 3 mL (w/v) sucrose, pH 7.0 bolus saline 3 1 1 CAB1.11i 5 5 1 1 Day 1 25 mM Phosphate (Na Intravenous 3 mL (naïve) and & K)/145 mM NaCl, bolus saline Day 8 5% (w/v) sucrose, pH 7.0 4 1 1 CEA 0.25 0.862 0.290 0.290 Day 1 PBS Intravenous 3 mL bolus saline 5 2 0 CAB1.11i 1 1 1 1.058 Day 1 PBS + 25 mM Intravenous 3 mL CEA 0.025 0.431 0.058 Phosphate (Na & bolus saline 6 2 0 CAB1.11i 1 1 1 1.290 Day 1 K)/145 mM NaCl, 5% Intravenous 3 mL CEA 0.25 0.862 0.290 (w/v) sucrose, pH 7.0 bolus saline

Blood samples (5 mL or 1 mL; EDTA anticoagulant) were collected via the chronic venous catheter and subcutaneous access port or by venipuncture of a femoral vein if the catheter became impatent. Blood samples were placed on ice for no longer than 30 minutes prior to processing. The blood samples were centrifuged at 3500 RPM for 10 minutes at 5° C. to harvest plasma. Each plasma sample was split into two approximately equal aliquots, transferred to separate polypropylene tubes, and stored at −70±10° C. For Group 3, the plasma from all 5 mL pre-dose samples (Day 1 pre-dose, Day 8 pre-dose, and Day 22) were split into 3 approximately equal aliquots, transferred to separate polypropylene tubes, and stored at −70±10° C. Voided urine was collected from each animal.

The results, shown in FIG. 25 and FIG. 26, show that CAB1.11i serum concentration profiles were similar after 2 doses, separated by one week, indicating that significant levels of neutralizing antibodies had not formed within this time frame. The elimination phase of CAB1.11i was similar in the presence or absence of CEA.

Having described the preferred embodiments of the present invention, it will appear to those ordinarily skilled in the art that various modifications may be made to the disclosed embodiments, and that such modifications are intended to be within the scope of the present invention.

One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The molecular complexes and the methods, procedures, treatments, molecules, specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention.

All patents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations that is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.

The invention has been described broadly and generically herein. Each of the narrower species and subgeneric groupings falling within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation removing any subject matter from the genus, regardless of whether or not the excised material is specifically recited herein. 

1. A CAB molecule comprising an unmodified amino acid sequence, the unmodified amino acid sequence being set forth in SEQ ID NO:2.
 2. A CAB molecule, the CAB molecule comprising an amino acid sequence modified from the amino acid sequence set forth in SEQ ID NO:2, the modification comprising at least one of the following positions: 12, 72, 283 or 586, wherein position numbering is with respect to SEQ ID NO:2.
 3. The CAB molecule according to claim 2, the CAB molecule comprising modifications at positions 12 and
 72. 4. The CAB molecule according to claim 2, the CAB molecule having the following modifications: 12, 72, 283 and
 586. 5. The CAB molecule according to claim 2, the CAB molecule having at least one of the following modifications: A12S, R72G, K283A or S586A.
 6. The CAB molecule according to claim 2, the CAB molecule comprising a CAB 1.11 molecule having the following modifications: A12S and R72G.
 7. The CAB molecule according to claim 2, the CAB molecule comprising a CAB1.11i molecule having the following modifications: A12S, R72G, K283A and S586A.
 8. A nucleic acid encoding a CAB molecule, the CAB molecule comprising an unmodified amino acid sequence, the unmodified amino acid sequence set forth in SEQ ID NO:2.
 9. A nucleic acid encoding a CAB molecule, the CAB molecule comprising an amino acid sequence modified from the amino acid sequence set forth in SEQ ID NO:2, the modification comprising at least one of the following positions: 12, 72, 283 or 586, wherein position numbering is with respect to SEQ ID NO:2.
 10. The nucleic acid according to claim 9, the CAB molecule comprising modifications at positions 12 and
 72. 11. The nucleic acid according to claim 9, the CAB molecule having the following modifications: 12, 72, 283 and
 586. 12. The nucleic acid according to claim 9, the CAB molecule having at least one of the following modifications: A12S, R72G, K283A or S586A.
 13. The nucleic acid according to claim 9, the CAB molecule comprising a CAB 1.11 molecule having the following modifications: A12S and R72G.
 14. The nucleic acid according to claim 9, the CAB molecule comprising a CAB1.11i molecule having the following modifications: A12S, R72G, K283A and S586A.
 15. A method of treating a subject in need thereof, the method comprising administering to the subject a CAB molecule and a prodrug that is a substrate of the CAB molecule.
 16. The method according to claim 15, wherein the subject is a mammal.
 17. The method according to claim 15, wherein the subject is a human.
 18. The method according to claim 15, wherein the CAB molecule comprises an unmodified amino acid sequence, the unmodified amino acid sequence being set forth in SEQ ID NO:2.
 19. The method according to claim 15, wherein the CAB molecule comprises an amino acid sequence modified from the amino acid sequence set forth in SEQ ID NO:2, the modification comprising at least one of the following positions: 12, 72, 283 or 586, wherein position numbering is with respect to SEQ ID NO:2.
 20. The method according to claim 15, wherein the CAB molecule comprises a CAB 1.11 molecule having the following modifications: A12S and R72G.
 21. The method according to claim 15, wherein the CAB molecule comprises a CAB1.11i molecule having the following modifications: A12S, R72G, K283A and S586A.
 22. The method according to claim 15, wherein the CAB molecule and the prodrug are administered at different times.
 23. The method according to claim 22, wherein the CAB molecule is administered before the prodrug so that the time between them comprises a dosing interval.
 24. The method according to claim 23, wherein the dosing interval is between about 1 day and about 14 days.
 25. The method according to claim 24, wherein the dosing interval is between about 3 days and about 10 days.
 26. The method according to claim 25, wherein the dosing interval is between about 7 days and between about 10 days.
 27. The method according to claim 25, wherein the dosing interval is between about 3 days and about 7 days.
 28. The method according to claim 27, wherein the dosing interval is about 3 days.
 29. The method according to claim 27, wherein the dosing interval is about 4 days.
 30. The method according to claim 27, wherein the dosing interval is about 5 days.
 31. The method according to claim 27, wherein the dosing interval is about 6 days.
 32. The method according to claim 27, wherein the dosing interval is about 7 days.
 33. The method according to claim 15, wherein the prodrug is a Melphalin-based prodrug.
 34. The method according to claim 33, wherein the Melphalan-based prodrug is GC-Mel. 